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Abstract 
Hypertension and atherosclerosis are two main risk factors for cardiovascular 
diseases (CVDs) in the modem world. CVDs are the top killers in the world. In 
addition, the management of CVD patients is costly, and places a heavy economical 
burden to the health care system. In order to search for an economical but effective 
solution, we seek from the old Chinese wisdom, the traditional Chinese medicines. As 
recorded in "Zhong yao fang ji xian dai yan jiu da dian"(中藥方齊1現代硏究大典)， 
Danshen-Gegen-Yanhusuo forms the simplest formula for treating cardiovascular 
disease, and Yanhusuo is mainly for analgesic purpose. Therefore, Danshen-Gegen 
formula becomes our target of study. In the present study, the anti-hypertensive and 
anti-atherosclerosis effects of Danshen-Gegen (DG) 7:3 water extract on aorta were 
being investigated. The action mechanisms of DG extract on vasodilation were also 
elucidated. 
To evaluate the anti-hypertensive effects of DG extract, in vivo model of 
spontaneous hypertensive rats (SHR) of 6-weeks old (for preventive study) and 
14-weeks old (for therapeutic study) were used. In study involving SHR rats, 
Wistar-Kyoto (WKY) rats of same age was used as a normotensive control, in which 
no treatments were given. For both preventive and therapeutic studies, daily oral 
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gavage o f D G extract was given to the SHR rats for 12 weeks. The systolic blood 
pressure (SBP) was measured biweekly by tail-cuff method. Our results showed that 
the positive control raloxifene (6.2mg/kg), DG extract of 90.2mg/kg (new clinical 
relevant dose) and 300 mg/kg (old clinical relevant dose) could significantly reduce 
the plateau of SBP in the prevention group, though not capable of reverting the SBP 
back to normal level. Besides, all three treatments could significantly lower the blood 
pressure of the therapeutic group. According to the blood lipid profile test, 90.2mg/kg 
of DG extract could significantly lower the cholesterol level, as compared with SHR 
control. 
Mechanistic studies of vasodilation can be divided into 2 parts: ex vivo 
mechanism elucidation and in vivo confirmation. The first part was performed using 
ex vivo isolated aorta ring organ bath. Aorta was pretreated with inhibitors or blockers 
for the elucidation of vasodilation pathways involved in DG extract-induced 
relaxation. Our results showed that 1 and 2mg/ml DG extract could induce full 
relaxation, and 0.5mg/ml of DG extract could induce about 50% relaxation of the 
aorta ring after U46619-induced contraction. The addition of inhibitors such as 
L-NAME and indomethacin, as well as denudation of aorta ring, could also give 
similar relaxation profiles to intact aorta ring. Hence, our results indicated that the 
vasodilation observed is not related to nitric oxide fNO) or prostacyclin, and is in fact 
endothelium-independent. Besides, TEA, a non-selective blocker of potassium 
channels, also inhibited the relaxation of lmg/ml DG extract to 50%. Furthermore, 
blockers of Kir and Ky channels also showed similar patterns of DG extract-induced 
relaxation to TEA, while blocker of KAip channel significantly inhibited the DG 
extract-induced relaxation at all doses. On the other hand, the addition of BKca 
channel blocker did not inhibit the DG extract-induced relaxation at all. These results 
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suggest the involvement of potassium channels, especially Kir, Ky and KAip channels 
but not BKca, in DG extract-induced relaxation. 
In the second part of the mechanistic studies, in order to confirm the results with 
in vivo model, SHR rats were fed with positive control raloxifene (6.2mg/kg), or DG 
extract (90.2mg/kg or 300 mg/kg) for 1 month, and aorta rings were isolated for study. 
In SHR rats, intake of raloxifene or DG extract did not significantly potentiate the 
increasing dose of acetylcholine-induced relaxation, in both the presence and absence 
of inhibitors or blockers. Aorta rings from SHR rats presented a significantly lower 
relaxation than those from WKY rats, induced by single and high dose of 
acetylcholine. Besides, intake of raloxifene or DG extract could slightly potentiate the 
relaxation in this condition. Moreover, it was found that the contractile force of the 
aorta was reduced by raloxifene or DG extract intake, which gave another explanation 
to the anti-hypertensive effect of DG extract. 
To investigate the effect of DG extract on anti-atherosclerosis, rabbits were 
initially fed with 1% cholesterol diet for 4 weeks. Then, 45.1mg/kg, 150mg/kg or 
450mg/kg of DG extract, or 300mg/kg vitamin E (serve as positive control) were 
orally fed daily for another 8 weeks with 1% cholesterol diet ad libitum. The 
intima-media thickness (IMT) of aorta, which reflects the degree of atherosclerosis, 
was significantly and dose-dependently suppressed by DG extract. Our results showed 
that DG extract had a slight hypolipidemic effect on cholesterol-fed rabbits, which 
partially explains its anti-atherosclerosis effect. However, both vitamin E and various 
dosages of DG extract did not have significant effect on plasma glucose level and 
lipid peroxidation. 
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In conclusion, our results confirmed the efficacy of DG 7:3 water extract on 
anti-hypertension and anti-atherosclerosis, possibly due to the reduction in contractile 
force, vasodilative and hypolipidemic effect of DG extract. The promising effects of 
DG extract on hypertension and atherosclerosis give scientific evidence towards our 
current clinical trial, and shear light to the future research of DG extract on 
anti-hypertension and anti-atherosclerosis. 
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Chapter 1 Introduction to Cardiovascular Disease. Hypertension and Atherosclerosis 
Chapter 1 
Introduction 
1.1 Introduction to Cardiovascular Disease，Hypertension and Atherosclerosis 
1.1.1 Cardiovascular Disease 
Cardiovascular diseases (CVD) are classified as coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, 
congenital heart disease, deep vein thrombosis and pulmonary embolism, etc. CVDs 
are the major cause of death and caused more than 17.1 millions death each year 
globally, in which a 7.2 million was due to coronary heart disease and 5.7 million due 
to stroke. CVDs accounted for about 30% of deaths in 2004 (World Health 
Organization, 2009). Low- and middle-income countries account for 82% of the 
deaths, due to higher exposure to risk factors, lower exposure to preventive measures 
and proper education, and less effective treatment and health care. Although the 
mortality in developed-countries is lower, the continuous health cares for CVD 
patients become a heavy economical burden in developed-countries. This trend is 
spreading to the developing countries, due to adverse lifestyle such as lack ofexercise, 
western style high fat/high caloric diet and increased tobacco use (Smith, et al., 2004). 
Therefore, CVD cause an economical loss and burden in the whole world, with an 
increasing trend in prevalence. 
In Hong Kong, heart disease is the second leading cause ofdeath in 2008, which 
accounts for 15% and 18% of mortality of male and female, respectively; while the 
cerebrovascular disease is the fourth leading cause of death, which accounts for 8% 
and 10% of mortality of male and female, respectively. Overall, CVD is the second 
and the first leading cause of death in Hong Kong for male and female, which account 
for 23% and 28% of mortality, respectively. The percentage is very close to first and 
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the second leading cause of death - malignant neoplasm, which cause 32.7% and 
26.7% of mortality for male and female, respectively (Department ofHealth, 2010). 
Hypertension is the major cause of hemorrhagic stroke (Rashid, et al., 2003， 
Smith, et al, 2004). It also increases the risk of recurrent myocardial infarction in 
patients with diagnosed coronary heart disease. Atherosclerosis is the major cause of 
atherosclerotic vascular disease - stroke, heart attack and peripheral arterial disease. 
As mentioned, stroke and heart attack were leading causes of death in Hong Kong in 
2008, and have a high chance of recurrence (Rodgers, et al., 1996). In rare case, 
atherosclerosis and hypertension would cause aortic aneurysm or dissection, which 
has extremely high mortality (Smith, et al., 2004). Therefore, management of 
hypertension and risk factors of atherosclerosis can broadly reduce the risk of a large 
variety of CVD events. 
1.1.2 Hypertension 
1.1.2.1 Background 
Hypertension refers to the elevated arterial pressure. The World Health 
Organization, International Society of Hypertension, European Society of 
Hypertension and the European Society of Cardiology definition ofdifferent stages of 
hypertension is listed in Table 1.1. It is a very common public health problem in 
developed countries. Although it is common, easy to diagnose and manage, the 
patients would dependent on the anti-hypertensive drugs and the complications of 
hypertension are usually lethal. In most case, the etiology is unknown. There are also 
difficulties in preventing (Chobanian, et aL, 2003) or curing (Hagemeister, et aL, 
2001). So, the patients would depend on the anti-hypertensive drugs, which is a large 
economical burden to the society and individuals. 
- 2 -
Chapter 1 Introduction to Cardiovascular Disease. Hypertension and Atherosclerosis 
Table 1.1 Classification of blood pressure for human adults 
Category Systolic Pressure (mmHg) Diastolic Pressure (mmHg) 
Optimal <120 <80 
Normal <130 <85 
High normal 130-139 85-89 
Hypertension 
Stage 1 (mild) 140-159 90-99 
Stage 2 (moderate) 160-179 100-109 
Stage 3 (severe) >180 >110 
1.1.2.2 Causes of Hypertension 
There are two types of hypertension - primary (essential or idiopathic) and 
secondary. Hypertension which caused by generalized or functional abnormalities are 
named as primary hypertension, while hypertension caused by disease of other 
structural organs or gene defects are named as secondary hypertension. However, 
regulation of blood pressure involves interactions among different systems -
peripheral and/or central adrenergic, renal, hormonal, and vascular system. This 
makes the mechanism elucidation becomes very difficult. 
A) Primary Hypertension 
Primary hypertension is defined as high BP in which secondary causes such as 
renovascular disease, renal failure, aldosteronism, or other causes of secondary 
hypertension are not present (Carretero and Oparil, 2000). There are some common 
abnormalities in hypertensive patient, which claimed to be the primary causes of 
hypertension as described below. 
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1) Environment 
There are several environmental factors that increase the risk of hypertension, 
including salt intake, obesity, occupation, alcohol intake, family size, and crowding. 
These factors thought to be an explanation of increasing blood pressure with age in 
wealthy countries (Burt, et cd., 1995, Kasper and Harrison, 2005). 
2) Salt Sensitivity 
In about 60% of hypertensive patients, the blood pressure is especially 
responsive to the amount of salt intake (Kasper and Harrison, 2005). Blood pressure 
of Asians and Blacks are more sensitive to salt intake than Caucasians (Jurgens and 
Graudal, 2004). The pathophysiology of this sensitivity is unknown. But the possible 
causes are modification of renin activity, chloride intake, calcium intake, insulin 
resistance, and "nonmodulation". 
3) Modification of Renin Activity 
Renin is an enzyme secreted by juxtaglomerular cells of the kidneys. It is linked 
with aldosterone in a negative feedback loop. However, it is essential for the 
production of angiotensin II. Angiotensin II causes vasoconstriction, induces the 
release of aldosterone to retain sodium and lose potassium (adrenal response), and 
acts on proximal tubules in kidneys to increase sodium reabsorption (renal response). 
In normotensive individuals, with sodium restriction, adrenal responses are enhanced 
and the renal vascular responses reduced. Sodium loading has the opposite effect. 
About 20% of hypertensive patients have their renin activity down-regulated 
(Kasper and Harrison, 2005). Thus, plasma aldosterone levels are not fully suppressed 
by dietary sodium salt loading, resulting an excessive amount of aldosterone that 
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retain sodium. They would have an increased extracellular fluid volume and can be 
managed by diuretics (Bhattacharya, et al., 2009, Brunner, et al., 1972). About 15% 
of hypertensive patients have their renin activity up-regulated. Their hypertension can 
be managed by antagonist of angiotensin II, suggesting the involvement of 
renin-angiotensin system (Kasper and Harrison, 2005). 
4) Chloride and Calcium Intake 
It is assumed that sodium plays a key role in hypertension. However, chloride 
and calcium ions may also play a role. Some studies showed that sodium salt without 
chloride actually fails to induce blood pressure elevation (Kotchen, et al., 1983, Kurtz, 
et al.，1987). Interestingly, a low calcium intake seems to be related to an increased 
blood pressure (Lal and Dakshinamurti, 1995). Nevertheless, calcium channel 
blockers are potent anti-hypertensive drugs. All of these indicate chloride and calcium 
ion play a role in hypertension. 
5) Insulin resistance 
Insulin resistance or hyperinsulinemia can lead to hypertension. An assumption 
is that the tissues involved in glucose homeostasis are not responsive, while the tissue 
involved in hypertensive process still work fine. Hypertension is caused by one or 
more of these three mechanisms: (1) Hyperinsulinemia induces sodium retention in 
kidneys and stimulate sympathetic activity, which can lead to an increase in blood 
pressure (Natali, et aI., 1993，Quinones-Galvan and Ferrannini, 1997); (2) Vascular 
muscle hypertrophy due to the mitogenic effect of insulin (Rizzoni and Agabiti Rosei, 
2006); (3) Insulin may modify ion transport across the cell membrane, causing 
cytosolic calcium accumulation in insulin-sensitive vascular smooth muscles 
(Lebeche, eta/.,2008). 
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6) Nonmodulation 
Some hypertensive patients have impaired modulation of adrenal and renal 
response to sodium restriction and loading. These patients would have difficulties in 
excretion of sodium through kidneys. The accumulation of sodium in the body would 
cause hypertension, and this type of hypertension seems to be salt-sensitive 
(Hollenberg and Williams, 2006). 
B) Secondary Hypertension 
Secondary hypertension is the complications of other diseases, like renal diseases 
or endocrine diseases. Renal diseases affect blood pressure by (1) changing the 
secretion of vasoactive molecules, like renin (Kalra, 2007), or (2) damaging the 
excretion function of kidneys leading to accumulation of salt and fluid (Campese and 
Nosrati, 1999). Endocrine diseases, mainly hormone-secreting tumour, induce 
hypertension mainly through the over-secretion of glucocorticoids or aldosterone, 
which cause retention of sodium (Sica, 2008). In rare case, it can be caused by tumour 
secreting epinephrine and norepinephrine, which act on adrenergic receptor and cause 
vasoconstriction (Amodeo, et cd., 1989). To treat the hypertension, curing the primary 
abnormality is the main goal. 
1.1.2.3 Current Western Management and Medication 
Current treatments to hypertension mainly include lifestyle modification and 
drug treatments. 
A) Lifestyle Modification 
Several changes to lifestyle are needed for all hypertensive patients: (1) Prevent 
stressful activities; (2) Low sodium, low cholesterol and fat, low alcoholic, low 
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caloric (for obesity patients) diet; (3) Regular aerobic exercise; (4) Quit smoking; (5) 
Weight reduction (for obesity patients); and (6) Control the risk factors contributing to 
atherosclerosis (Kasper and Harrison, 2005). 
B) Drug Therapy 
1) Diuretics 
Thiazides are most frequently used in this family. The acute function is diuresis 
(increase excretion of water through urine) by impairing sodium reabsorption and 
reduces the blood volume (Wilson and Freis, 1959). In long term intake, reduction in 
peripheral vascular resistance was found in some studies (Freis, 1983). However, its 
possible side effects include potassium depletion, hyperglycemia, hyperuricemia, 
hypercholesterolemia, dermatitis, purpura, depression, and hypercalcemia. 
2) Angiotensin-Converting Enzymes (ACE) Inhibitors 
ACE inhibitors act on multiple ways: (1) Inhibit the production of angiotensin II, 
a potent vasoconstrictor; (2) Inhibit the degradation of bradykinin, a potent 
vasodilator; (3) Modify prostaglandin production; and (4) Modify the activity of the 
adrenergic nervous system (Bravo and Tarazi, 1979). It is effective for most 
hypertensive patients, even the malignant ones. There are also fewer side effects, 
include cough, hyperkalemia in patients with renal disease and angioedema. 
3) Angiotensin Receptor Antagonists 
The effect of these antagonists is similar to ACE inhibitors, but with a higher 
selectiveness. They compete with angiotensin II for the binding to angiotensin II ATi 
receptor subtype (Tofovic, et al., 1991). Therefore, they have fewer side effects than 
ACE inhibitors, including excessive cough or angioedema. 
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4) Calcium Channel Blockers 
They act on ai subunit of the L-type voltage-dependent calcium channels (Luft 
and Haller, 1993). It acts to reduce calcium entry to the cell, lower the cytosolic 
calcium and causing vasodilation. The side effects include tachycardia, flushing, 
gastrointestinal disturbances, hyperkalemia, edema, and headache. 
5) p_adrenergic Receptor Blockers 
The actions of P-adrenergic hormone include the elevated heart rate and 
strengthen the contractile force of the heart. The hormone also induces renin secretion 
in juxtaglomerular cells in kidneys. Therefore, the blockers of its receptor can reduce 
the cardiac output and renin secretion (Distler, et al., 1978). P-adrenergic receptor 
blockers are commonly use with vasodilator, which causes increased heart rate, or use 
with diuretics, which causes increased renin activity (Kasper and Harrison, 2005). 
Side effects includes dizziness, depression, bronchospasm, nausea, vomiting, diarrhea, 
constipation, heart failure, fatigue, Raynaud's phenomenon, hallucinations, 
hypertriglyceridemia, hypercholesterolemia, and psoriasis 
6) Vasodilator 
Vasodilator causes relaxation in vascular smooth muscle cells. However, the 
effect usually compensate by increased heart rate by homeostasis of the body (Kasper 
and Harrison, 2005). Therefore, they are mainly used for hypertensive emergencies by 
intravenous injection. Side effects include tachycardia, nausea, vomiting, and fluid 
retention. 
The above medications can be used in single drug or in combination, depending 
on the degree and malignance of the hypertension. Patients with other diseases, 
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especially renal diseases, have to pay attention to the use of drugs, as many of them 
would have side effects that possibly overload or damage specific organs. 
1.1.3 Atherosclerosis 
1.1.3.1 Background 
Atherosclerosis is the thickening of artery walls due to the build up of foam cells 
and smooth muscles. It progresses slowly in human, usually takes years to decades to 
build up. Atherosclerotic lesion initiates at branching points of arteries and regions 
with disturbed blood flow, and in a discontinuous spots manner. The condition 
remains asymptomatic for a long time, until the blood flow is seriously occluded. 
Chronic symptoms include reproducible angina pectoris after exercise and 
intermittent claudication. Acute clinical expressions differ according to the location of 
atherosclerosis. Atherosclerosis of coronary arteries causes myocardial infarction. 
Atherosclerosis of cerebroarteries causes stroke and mini stroke. Peripheral 
atherosclerosis causes gangrene. The ruptured plaque has a chance to become 
embolus and cause embolism, which cause ischemia in other organs. Most of the 
acute clinical expressions have a high mortality rate, and strongly affect the quality of 
life of patients after recovery. 
Structure of Arteries 
Arteries are known to have three distinct layers - tunica adventitia, tunica media and 
tunica intima. Intima is the innermost layer in arteries, which consists of a single layer 
of endothelial cells. Intima is in direct contact with blood. Media is the middle layer 
in arteries, which consists of smooth muscle cells and elastic fibers. Media is 
responsible for contraction and relaxation of arteries. Adventitia is the outermost layer 
of arteries, which consists of collagen and some elastic fibers. Adventitia anchors the 
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arteries to nearby tissues and keeps them in position. 
1.1.3.2 Pathogenesis of Atherosclerosis 
Initiation of Atherosclerosis 
Atherosclerosis is initialized by the fatty steak accumulation. The early lesion 
starts at the infiltration of low density lipoprotein (LDL) to the intima. LDL binds 
with the proteoglycan molecules of the arterial extracellular matrix, and retain in the 
intima area (Williams and Tabas, 2005). The matrix separates LDL from the plasma 
antioxidants, and favors the oxidation. Oxidation of trapped LDL by reactive oxygen 
species (ROS) and free radicals occurs, and oxidized LDL (oxLDL) is the final 
product (Chisolm and Steinberg, 2000). 
Leukocyte Recruitment 
After the fatty steak accumulation, recruitment of leukocytes occurs. OxLDL can 
induce cytokine release and trigger the local inflammatory response. By expression of 
adhesion molecules (Vascular cell adhesion molecule-1 (VCAM-1)) or receptors, 
monocytes and lymphocytes attach to the adhesion molecules (Iiyama, et al., 1999). 
OxLDL also elicits the production of chemoattractant cytokines such as monocyte 
chemoattractant protein 1 (MCP-1). MCP-1 directs monocytes and lymphocytes to 
penetrate through the endothelium and stay in the intima layer (Libby, 2002). 
Foam cell Formation 
After migration, monocytes differentiate into macrophages. The macrophage 
expresses the scavenger receptors to endocytose oxLDL (van Berkel, et al., 2005). 
Some of them can leave the intima and clear the LDL from the arteries. However, if 
the entry of LDL is faster than the clearance of LDL, the macrophages take up excess 
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LDL and transform into foam cells (Kasper and Harrison, 2005), named after its 
foamy appearance under microscope. Foam cells secrete pro-inflammatory cytokines 
that worsen the local responses to inflammation and ROS. Foam cells also secrete 
matrix metalloproteinases (MMPs), which degrade the extracellular matrix 
(Rajavashisth, et al” 1999). The strength of the plaque's fibrous cap is reduced, and 
rupture. As a consequence, foam cells-originated pro-coagulant protein tissue factor 
contacts with the blood (Williams and Tabas, 2005). Foam cells are trapped in the 
blood clot, and undergo apoptosis. The dead foam cells mediate more local 
inflammatory response and form lipid-rich "necrotic core" (Williams and Tabas, 2005) 
in more advanced atherosclerotic lesions. The whole process is illustrated in Fig 1.1. 
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Fig 1.1 Process of leukocyte recruitment and foam cells formation (Extracted 
from Libby, 2002) 
Smooth Muscle Migration 
After rupture of plaque, blood coagulation is induced by thrombin and other 
coagulants. On the other side, thrombin activates wound healing response stimulate 
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smooth muscle cells proliferation. At the same time, activated platelets secrete 
platelet-derived growth factor (PDGF), contributing to the smooth muscle cells 
migration (Badimon, et al., 1993), and transforming growth factor-P (TGF-p), 
stimulating collagen production (Border and Noble, 1994). With increased smooth 
muscle cell proliferation, migration and extracellular matrix reconstruction, intima 
further thicken towards an inward direction. Finally, a narrower lumen is formed (Fig 
1.2). The blood flow is restricted, which may lead to observable symptoms like angina 
pectoris during physically demanding activities. In serious cases, ischemia of the 
destination organ is resulted. 
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Fig 1.2 Schematic of the life history of an atherosclerotic plaque (Extracted 
from Libby, 2002) 
1.1.3.3 Current Western Treatment and Medication 
There is not yet a treatment protocol for atherosclerosis. However, risk factors 
that contribute to atherosclerosis have been identified. By correcting some of the 
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modifiable risk factors, the progress of atherosclerosis can be slowed down. These 
risk factors include hypercholesterolemia, hypertension, disregulation of coagulation 
or fibrinolysis, hyperhomocystinemia, insulin resistance and inflammation. 
Lipid-lowering Therapies 
Most well-known lipid-lowering drug is "statin". Statin is a 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. 
HMG-CoA reductase is a major enzyme participating in cholesterol synthesis in liver. 
By inhibiting it, the endogenous production of cholesterol halt, and the level of liver 
cholesterol would decrease (Ginter and Simko, 2009). The liver senses the reduction 
in liver cholesterol, and draws LDL and very low density lipoprotein (VLDL) from 
the bloodstream as a feed-back. LDL and VLDL would be consumed by liver to 
produce bile salt and excreted. 
Statin also found to be increasing endothelium-dependent vasomotion and reduce 
thrombosis. These functions are suspected to be related to improved endothelial 
function. The final outcome is the stabilization of the atherosclerotic plaque (de 
Lorenzo, et al, 2006). 
Anti-hypertensive Therapy 
The therapy is as stated in 1.1.2.3. From other studies, there is a relationship 
between hypertension and atherosclerotic risk. And drug treatment of hypertension 
can also reduce the risk of stroke and heart attack. 
Anti-thrombosis 
In complication of atherosclerosis, like stroke or myocardial infarction, the 
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triggering factor is thrombosis. Anti-thrombotic drug, like aspirin, is a solution to this. 
Aspirin is a cyclooxygenase-1 inhibitor and cyclooxygenase-2 action modifier. 
Low-dose aspirin treatment (81 mg to 325 mg daily) can inhibit most of the 
production of thromboxane A2, a prothrombotic molecule, in platelets (de Gaetano, et 
al., 1986). It is also used to control stable ischemic heart disease, and in treatment of 
acute heart failure and stroke (Calverley and Roth, 1998). However, it has side effects 
of increased chance of hemorrhagic stroke, gastrointestinal bleeding, and prolong 
bleeding after operation. 
Advance Stage of atherosclerosis 
If atherosclerosis developed into ischemic heart disease, drug therapies are used 
to treat the angina pectoris. Drugs involved include vasodilator 0Slitrites), 
p-adrenergic blocker, and calcium channel blockers mentioned in 1.1.2.3. Surgery is 
also a choice for coronary revascularization (Kasper and Harrison, 2005). 
Percutaneous Coronary Intervention (PCI) 
PCI is also known as angioplasty. It was first developed by Andreas Gruentzig 
in Zurich, Switzerland in 1977. The surgery involves the use of a balloon catheter. 
The catheter penetrates through the skin and goes along the lumen of the artery with 
the guiding by X-ray. After reaching the destination, the balloon is inflated to open up 
the artery (Gruntzig, et aL, 1979). A stent is placed at the inflated area to keep it 
expanded 0^ewsome, et al,, 2008). It is mainly for stenosis of one or two coronary 
vessels. The complication risk is about 2.1% to 12.7%. The possible, major side 
effects include arrhythmias, vascular complications, contrast reaction, renal failure 
and haemodynamic complications. The minor side effects include contrast reaction, 
nausea, and groin complications. Restenosis is possible in revascularized vessels 
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(Department ofMedicine, 2007). 
Coronary Artery Bypass Grafting (CABG) 
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fact that CABG is a major surgery. This 
surgery is mainly for stenosis of two or more coronary arteries, especially ones with 
diabetes. The mortality is about 3% to 4% (Queen Mary Hospital, 2008). 
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1.2 Selection and Introduction of Current Chinese Medicine Formula 
1.2.1 Cardiac Syndrome in Traditional Chinese Medicine 
Heart-related diseases were recorded in ancient Chinese medicine records, 
mainly as heart pain, extending to the back and shoulder, and difficulties in breathe. It 















These symptoms are highly similar to the clinical manifestation of angina pectoris, 
including (1) chest discomfort presented as a pressure, heaviness, tightness, squeezing, 
buming, or choking sensation; and (2) anginal pains in heart, spreading to upper 
central abdominal region, back, neck area, jaw, or shoulders. Therefore, “胸搏心痛” 
is believed to be Chinese medicine version of angina pectoris, which mainly due to 
ischemic heart diseases. 
The main treatments in Chinese medicine involve the use of circulation 
promoting herbs, such as Radix Salviae miltiorrhizae (丹參)，Rhizoma Corydalis (延 
胡索),Flos Carthami (紅花),Rhizoma Chuanxiong ( J I | ^ ) , and Radix Curcumae (變 
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金).There is also a famous formula that mentioned above "gua lou xie bai ban 
xia tang"(瓜萎薤白半夏湯)，which was used for a very long time and widely 
investigated in China (張建敏 et al., 2004，連樂燊，et al., 2006,劉貴京，et al., 
2004). In the commercial market, the heart tonic drug Kyushin (救/L�) is also made 
from traditional Chinese medicines. The above evidences show the effectiveness of 
traditional Chinese medicine on treatment ofheart diseases. 
1.2.2 Traditional Chinese Medicine as an Complementary or Alternative 
Medicine 
Complementary and alternative medicine (Campbell and Falck) is a group of 
diverse medical and health care systems, practices, and products that are not generally 
considered to be part of conventional medicine. Complementary medicine is 
used together with conventional medicine, while alternative medicine is used 
to replace conventional medicine. Traditional Chinese Medicine (TCM) falls into the 
type of whole medical systems, which defined as systems that are built upon complete 
systems of theory and practice (Bethesda, 2007). Westem medicine is simple and 
effective in clearly located and well defined disease. However, when the pathology is 
more complicated, Westem medicine becomes ineffective and defective. The 
disappointment leads to the use of CAM (Leung, et al., 2003). 
In United States, an estimated 3.1 million US adults had used acupuncture in the 
previous year. In the same study, natural product, like herbs, is the top alternative 
therapy used, with 17 percent of US adult using it (Bethesda, 2009). In China, 
Chinese medicine hospitals also provide diagnostic and treatment services in Westem 
medicine (Leung, et aL, 2003). Some hospital of integrated therapy use TCM as 
treatment in the problem areas of Westem medicine, such as vascular diseases, 
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dermatitis and rheumatology. Despite of the widespread use of TCM, NCCAM stated 
that TCM is "Although TCM is used by the American public, scientific evidence of its 
effectiveness is, for the most part, limited." (Bethesda, 2009). Therefore, scientific 
researches were widely done to identify the efficacy and mechanisms of action of 
TCMs. 
Scientific researches show TCMs are effective on cardiovascular disease (Li, et 
al., 2009, Zhao, et cd., 2010, Zhou, et al., 2003), rheumatic diseases (Lu, et al.，2009, 
Zhang, et cd.’ 2010), various cancers (Li, et aI., 2010, Luk, et al., 2007, Meng, et al., 
2009, Wang, et al., 2010，Woo, et al., 2007) and dermatitis (Makino, et al., 2008, 
Zhang, et al., 2005). These results further support the use ofTCM as CAM. 
1.2.3 Selection ofTCM Formula from Pharmacopoeia 
As recorded in "Zhong yao fangji xian dai yanjiu da dian"(中藥方齊昨見代硏究 
大典)(Huang and Shi, 1996), the cardiovascular disease treatment formula were 
identified. Among them, the simplest formula consisted of three herbs, Radix Salviae 
miltiorrhizae (Danshen), Radix Puerariae (Gegen) and Rhizoma Corydalis (Yanhusuo) 
in a weight ratio of 6:3:1. The formula is first used in the clinical trial for treatment of 
coronary heart disease in 1986. The formula was found to be effective in controlling 
angina pectoris, lowering triglyceride and improving electrocardiogram. This formula 
was used as the basic formula for our study. 
1.2.3.1 Compound Formula 
Traditionally, Chinese herbal medicine was prescribed in compound formula. 
Comparing with the single herb, compound formula is more potent and have less side 
effects (Lei, et al, 1995). Through the synergistic effect or formation or new 
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compounds, the formula can have higher effectiveness. A single Chinese herbal 
medicine contains a pool of active compounds, which contributes to the 
multi-functional Chinese herb. When only one or one group of function is needed, the 
other functions become side effects. Through the antagonistic effect, the formula can 
reduce or remove unrelated effect or side effects. Thus, compound formula ofherbs is 
a special and advantageous tradition in Chinese medicine. In our research, we keep 
this tradition to attain a higher efficacy in cardiovascular disease treatments. 
1.2.4 Introduction to Constitutional Herbal Medicine 
Three herbal medicines would be introduced in this part. Danshen and Gegen 
were included in our currently investigated formula in a weight ratio of 7:3. The 
exclusion of Yanhusuo (which originally present in the formula) in the current 
formula would also be explained. 
1.2.4.1 Danshen (Radix Salviae miltiorrhizae) 
Salvia miltiorrhiza, which is called Danshen (丹參）in Chinese, is widely used 
for heart-related diseases in China for long time. The root and rhizome are used. In 
the perspective of traditional Chinese medicine, Danshen is bitter, a bit cold and 
belong to heart and liver circulation. It has the function of promoting blood circulation, 
clearing heat from blood, healing carbuncle, and tranquilizing the mind. It was first 
recorded in《神農本草經》&8“主心腹邪氣……破癥除痕’止煩滿°”.Intraditional 
use, it is mainly for treatment of amenorrhea, dismenorrhea or abdominal pain after 
labour. It can be used for treatment of chest and heart pain, or anxiety and insomnia 
due to “heat” (Lei, et al., 1995). 
In scientific studies, Danshen also have multiple pharmacological functions. The 
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cardiovascular related ones include: (1) anti-thrombosis (Shen and Li, 1997); (2) 
cardioprotection (Cao, et al, 2003); (3) anti-hypertension (Kang, et al., 2002); (4) 
anti-atherosclerosis (Wu, et aL, 1998); and (5) improve microcirculation in brain and 
heart (Yu, 1988). Other functions include promotion of repair and regrowth of the 
� ischemia-damaged cells, anti-oxidation fNiu, et al.’ 2000) and heptoprotection 
(Wasser, et al, 1998). 
1.2.4.2 Gegen (Radix Puerariae Iobatae) 
Pueraria lobata, which is called Yegegen (野葛根)in Chinese, has a long 
history being drug and food in China. Its root was used in this experiment. In the 
perspective of traditional Chinese medicine, Gegen is bitter, spicy, and cold and 
belong to pancreas and stomach circulation. It has the function of purging heat, 
increase saliva secretion, improving the "yang qi", curing diarrhea, and detoxification. 
It was first recorded i n《神農本草經》a s “主消渴，身大熱，幅吐，諸搏，起陽 
氣，角军諸毒 ° ”. In traditional use, it is mainly used to treat diseases caused by weather 
change, disease with symptoms of thirsty, measles and diarrhea (Lei, et al., 1995). 
In scientific studies, Gegen also have multiple pharmacological functions. The 
cardiovascular related ones include: (1) anti-hypertension (Sun, et al, 2007); (2) 
lowering plasma cholesterol level (Yan, et al., 2006); (3) reduce heart rate; and (4) 
anti-thrombosis (Choo, et al, 2002). Other functions include anti-diabetic (Xu, et al, 
2005) and anti-oxidation (Han, et al., 2005). 
In the latest edition of Chinese Pharmacopoeia (2010)，another species of Gegen, 
Pueraria thomsonii, was mentioned. The contents of the components daidzein， 
daidzin and puerarin in Pueraria lobata are three to five times higher than that of 
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Pueraria thomsonii. Due to this, Pueraria lobata has more potent (about five times 
stronger) anti-oxidant activity than Pueraria thomsonii (Jiang, et cd., 2005). Besides, 
Pueraria lobata was also shown to exhibit higher efficacy on vasodilation (Chan, 
2006) and hence it was chosen to be used in our study. 
1.2.4.3 Yanhusuo (Rhizoma Corydalis) 
Corydalis yanhusuo, which is called Yanhusuo (延胡索）in Chinese, is also 
widely used in China for long time. The rhizome is cooked in boiling water and dried 
for use. In the perspective of traditional Chinese medicine, Yanhusuo is spicy, bitter, 
and warm and belong to liver, pancreas and heart circulation. Its main functions are 
promoting blood and "qi" circulation, and pain killing. It was first recorded in 《雷公 
炮炎論》a s “、冶/[>痛欲死�”.In traditional use, it is mainly used to cure blood 
circulation problem or heart related pain. Sometimes it is used for other analgesic 
purposes (Lei, et al., 1995). 
1.2.4.4 Composition of the Final Formula Used in the Present Study 
The main function of Yanhusuo is pain killing, although it also has mild 
cardiovascular effects. The inclusion of this herb may hide the pain in early stage of 
cardiovascular disease, like stroke, or heart attack. This may lead to a delay in 
treatment, which would adversely affect the survival of the patients. For the safety of 
the patient and considerably small contribution to the cardiovascular function, 
Yanhusuo is excluded from the formula. So the final formula consists of Danshen and 
Gegen. With 1 part of Yanhusuo replaced by 1 part of Danshen, the Danshen-Gegen 
ratio becomes 7:3. 
The animal doses used in this study were calculated according to the new and old 
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clinical doses. For example, the new clinical dose includes a treatment of 2 capsules 
per day. Each 450 mg capsule (Danshen: Gegen 7:3) contains 436.5 mg herbal extract 
and 13.5 mg excipient. 
•:• 2 capsules per day, 436.5 mg x 2 = 873 mg 
• For a 60kg human (average weight of adult human), 
HED = 873 mg/ 60kg 
=14.55 mg/kg 
•:• Rat dose = 14.55 mg/kg x 6.2 
二 90.2 mg/kg 
• Rabbit dose = 14.55 mg/kg x 3.1 
=45.1 mg/kg 
Conversion factors of 6.2 and 3.1 are for the conversion of human equivalent 
doses to rat dose and rabbit dose, respectively, based on body surface area. The 
conversion is recommended by U.S. Department of Health and Human Services, Food 
and Drug Administration (U.S. Department of Health and Human Services, 2005). 
Similarly, for the old clinical dose, the equivalent animal doses calculated were 
300 mg/kg for rat and 150 mg/kg for rabbit. 
1.2.5 Previous work on Danshen-Gegen Formula and its limitations 
In previous studies conducted within our research team, Danshen-Gegen 
compound formula was shown to have anti-oxidative (Chan, 2006, Koon, 2006), 
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cardioprotective, vasodilative (Chan, 2006), anti-hypertensive (Tam, 2004) and 
anti-atherosclerotic (Koon, 2006). In in vitro and in vivo systems, the formula can 
scavenge free radicals and increase the expression of antioxidant enzymes (Koon, 
2006, Leung, 2003). It also induced vasodilation in ex vivo rat aorta (Chan, 2006). 
The in vivo anti-atherosclerotic effect was shown in terms of area of coverage of 
plaque in rabbits' aorta (Koon, 2006). 
However, there are limitations in these experiments. Some of the experiments 
were done using Radix Puerariae thomsonii instead of Radix Puerariae lobatae. Radix 
Puerariae lobatae is having much higher bioactivity than Radix Puerariae thomsonii, 
and was used in our clinical trial and will be used in present study. Some of the 
experiments were done using a different weight ratio of Danshen and Gegen. The 
mechanism elucidation did not include all types of potassium channels, but indeed 
potassium channels involvement was found. The mechanism elucidation included a 
single dosage of Danshen-Gegen only. For anti-atherosclerotic study, only the amount 
of plaque, instead of the actual thickness of the plaque, was measured. Therefore, the 
findings were incomplete, and there may be inconsistence between different data. 
To improve these, Danshen-Gegen of weight ratio 7:3 would be used. Same 
batch of water extract is used throughout all experiments to prevent inconsistence in 
this study. 
In anti-hypertension part, the mechanism elucidation included all pathways of 
vasodilation, with investigation of the involvement of all four types of potassium 
channels. Different dosages of DG extract were used including dosage that range from 
full to no vasodilation. The incubation time after addition of DG extract was extended 
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to 2 hours, in order to ensure no vasodilation effect was missing. 
In anti-atherosclerosis part, intima-media thickness measurements were used to 
replace the plaque amount for quantification of extent of atherosclerosis, which 
reflects the situation more accurately. 
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1.3 Objectives of the Present Study 
The objective of the present study is to further investigate the vasodilative and 
anti-atherosclerotic efFects of DG 7:3 water extract, in order to give a full picture to 
cardiovascular tonic effect ofDG formula. 
The main objectives include: 
1) Verification of previous results and investigation of the new aspects using a single 
batch of DG extract (produced according to standardized extraction protocol) with 
Pueraria lobata as Gegen, which enabled comparison of results with previous 
studies, in which a variety of DG ratio, extraction solvents were used and the 
closely related species of Pueraria, Pueraria thomsonii was used as Gegen. 
2) Verification of DG extract's vasodilative effect in hypertensive rats. 
3) Mechanism elucidation of the vasodilative effect of DG extract (in a concentration 
range) on isolated rat aorta rings, especially the potassium channels which are not 
investigated before. 
4) Study the anti-atherosclerotic effect of DG extract in terms of intima-media 
thickness in cholesterol-fed rabbits. Although the coverage of plaque in aorta was 
investigated in previous studies, the main factor causing the blockage of aorta is in 
fact intima-media thickening. 
5) Determination of whether DG extract has anti-oxidative and hypolipidemic effects 
on cholesterol-fed rabbits, as these effects hinder the progression of intima-media 
thickening. 
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Chapter 2 
Experimental Design and General Methodology 
2.1 Source and Authentication of Raw Herbs 
Dried roots of Salvia miltiorrhiza (Danshen abbreviated as D), grown in Sichuan 
province, and dried roots of Pueraria lobata (Gegen abbreviated as G), grown in 
Guangdong province were purchased. The herbs were firstly morphologically 
authenticated by a botanist, Dr. Cao Hui (National Engineering Research Center for 
Modernization of TCM, Zhuhai, Guangdong, China). Thin-layer chromatography 
(TLC) was then utilized to identify the herbs by checking against reference herbs and 
their corresponding chemical markers, according to Chinese Pharmacopoeia 2005. 
Voucher specimens were deposited at the museum of ICM, CUHK, with the following 
voucher numbers (Table 2.1): 
Table 2.1 Voucher numbers of the herbs used in the study 
Name of Herbs Voucher Specimen Numbers 
Radix Salviae miltiorrhizae (丹參） 2008-3166b 
Radix Puerariae lobatae (野葛根) 2008-3167b 
With the authenticated herbs, extraction was performed. The raw herbs Danshen 
and Gegen were used in the weight ratio of 7:3. Extraction was carried out as below: 
• Raw herbs were washed gently with tap water to remove dust and other 
contaminants 
• The herbs were cut and weighed in the ratio of 7:3 
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• The herbs were extracted with water in 1:10 (w/v) under reflux for 1 hour, 
then the water extract was collected and the process was repeated for another 
hour 
• The extracts were pooled and centrifuged at 7700 x g for 20 minutes and 
supernatant was filtered and collected 
• The extract was concentrated using rotary evaporator under reduced pressure 
•:• The concentrated extract was dried by lyophilization 
• The dried powdered extract was stored in dry location 
The yield of extraction was around 35-40%. The same batch of herbs and water 
extracts were used throughout the present study. 
» 
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2.2 Materials 
Krebs solution stock (lOX) was prepared by dissolving 68.96g ofNaCl, 3.5g ofKCl, 
3.675g 0fCaCl2 • 6H2O, 2.033g 0fMgCl2 • 6H2O and 1.63g ofKH2PO4 in 1 liter of 
distilled water. The stock was diluted to IX using distilled water with the addition of 
2.433g glucose and 2.1g NaHCO3 per liter. Krebs solution (IX) contained 118mM of 
NaCl, 4.7mM of KC1, 2.5mM of CaCl2 • 6H2O, lmM 0fMgCl2 • 6H2O, 1.2mM of 
KH2PO4, 13.5mM of glucose and 25mM ofNaHCO3. The pH was adjusted to 7.4 and 
storedat-4°C. 
Glucose assay kit was purchased from BioSystems S.A. (Barcelona, Spain). 
Trichloroacetic acid (TCA) was purchased from Merck (Darmstadt, Germany). 
Phosphate-buffered saline (PBS) (lOX), pH 7.4 was obtained from Invitrogen (CA, 
USA). It was diluted using distilled water. 
Ketamine 10% and Xylazine 2% were purchased from Alfasan (Woerden, Holland) 
through Laboratory Animal Services Centre. 
Spontaneously hypertensive rats (SHR), Wistar-Kyoto (WKY) rats and 
Sprague-Dawley (SD) rats were purchased from the Laboratory Animal Services 
Centre of the Chinese University of Hong Kong. All animals were kept at room 
temperature with a regular 12-hour lightAiark cycle, and maintained on a standard 
rodent chow and water. 
Rodent chow (Labdiet 5P14) were purchased from Purina Mills LLC (Minnesota, 
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USA). The diet was kept unopened in dry condition and protected from light until use. 
New Zealand White Rabbits were purchased from the Laboratory Animal Services 
Centre of the Chinese University of Hong Kong. All animals were kept at room 
temperature with a regular 12-hour light/dark cycle, and maintained on 
standard/special rabbit chow and water. 
Standard rabbit chow (Guinea Pig and Rabbit Pellets) and rabbit chow with 1% 
cholesterol (SFOO-221) were purchased from Specialty Feeds Pty Ltd. (Glen Forest, 
Australia). The diet was kept unopened in dry condition and protected from light until 
use. 
All triglyceride and cholesterol LiquiColor Tests were purchased from Stanbio 
Laboratory (Texas, USA). All H&E staining related reagents were supplied by 
division of anatomy. All other reagents were purchased from Sigma-Aldrich Co. (St. 
Louis, MO, USA). 
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2.3 Ethical Approval 
All animal studies were conducted under the license from Department of Health, 
Hong Kong SAR, People's Republic of China, and the procedures were approved by 
the Animal Experimental Ethics Committee of the Chinese University of Hong Kong 
(Ref: 09/016/MIS, 09/064/MIS and 09/065/MIS). 
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2.4. General Methods 
2.4.1 Blood Pressure Measurement 
Rats were put into the rodent holders so that their noses protruded through the 
front of nose cones while the tails exit through the rear hatch opening of the holder, to 
give a comfortable condition for the rats (Fig 2.1). Then, the occlusion cuff and the 
volume pressure recording cuff were mounted on the rat's tail. After 10 minutes of 
acclimation, the pressure measurement was obtained using CODA system (Kents 
scientific Co., USA) with CODA6 Software, installed in a laptop computer with 
Windows XP system. Six animals were handled under warming at the same time. 
Minimum of five data of similar systolic blood pressure were obtained for each 
animal. Average systolic blood pressure of each rat was then calculated. 
«MiMMM»^^iiimiiiiii^^^^m^^ 




c a ' r t t 1 
Fig. 2.1 Setup ofCODA system 
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2.4.2 Blood Profile Measurement 
Blood Sample Storage and Preparation 
Blood collected from the animals were injected into vacuum tubes with sodium 
heparin as the anti-coagulant. The tubes were stored in ice during transport. By 
centrifugation of whole blood at 1500 x g for 10 minutes at 4°C, plasma was collected 
as the supernatant. Plasma was then stored in 1.5ml eppendorf tube and kept frozen at 
-80°C in deep freezer. All assays were performed within 1 month after sampling. 
Blood Profile Assay 
For all lipid and glucose profile assays, the standards were 2-fold, 4-fold, 8-fold 
and 16-fold diluted. For total, HDL- and LDL-cholesterol assays, the samples of 1% 
cholesterol treated rabbits were 10-fold diluted. The procedures of all assays were 
prepared according to technical manuals of the manufactures 
In total cholesterol, triglyceride and glucose assays, lO i^l of sample was added 
into the 96-well plate in duplicate. The reaction reagent (300 i^l) for each assay was 
added to each well and incubated at 37°C for 5 minutes. After incubation, absorbance 
was measured at 500nm. 
In HDL- and LDL-cholesterol assays, lO i^l of sample was added into the 96-well 
plate in duplicate. The reaction reagent A (210^1) was added to each well and 
incubated at 37°C for 5 minutes. After incubation, 70 1^ of reaction reagent B was 
added to each well and incubated at 37�C for another 5 minutes. Finally, absorbance 
was measured at 600nm and 700nm. Differences in absorbance at 600nm and 700nm 
were used to determine the cholesterol concentration. 
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^ , 丨 r^  4>c 1 Sample OD600nm 一 OD700nm 作丨广 ^^ ^^  I 
Chol. Conc. ofSample= — xChol. Conc. ofSTD I 
STD OD600nm 一 OD700nm | 
Anti-oxidation assay 
In thiobarbituric acid reactive substances (TBARS) assay, plasma concentrations 
of TBARS were determined. Thiobarbituric acid (TBA, 67mg) was dissolved in 1ml 
DMSO with addition of 9ml H2O. Trichloroacetic acid (TCA, 10%w/v) was prepared 
using distilled water. The standard 1,1,3,3-tetramethoxypropane (TMOP, 4.167^iL of 
500|iM) was dissolved in 1ml ethanol and 49ml of water was added. The mixing 
protocol for TMOP standards is shown in Table 2.2. 
Table 2.2 The mixing protocol for TMOP standard 
Concentrations of TMOP (fiM) H^O (jil) Volume of TMOP used (jU) 
0 500 
0.625 500 500 from 1.25 i^M standard 
1.25 500 500 from 2.5 i^M standard 
2.5 500 500 from 5^ iM standard 
5. 500 500 from lO i^M standard 
10 800 200 from 50^M standard 
50 500 500 from 1 0 0 _ standard 
100 800 200 of500^iM stock 
Plasma samples (200 i^l) were placed into a labeled 1.5mL micro-centrifuge tubes. 
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Ice cold TCA (10% w/v) (400 i^l) was added in each tube and incubated in ice for 15 
minutes to precipitate protein. After that, the samples were centrifuged at 2200 x g for 
15 min at 4°C. Supematant/standard (250p,l) in each tube was transferred to a new 
1.5ml eppendorf tube. After that, 250p,l of 0.67% (w/v) TBA was added to each tube 
and incubated in 100°C for 60 min. The samples/standards were cooled down in ice. 
150^1 of each sample/standard was loaded into a 96-well plate in duplicate. 
Absorbance at 532nm was recorded. 
The absorbance and concentration of the standards were used to plot the standard 
curve. The slope was determined. The amount of TBARS was calculated using the 
formula below: 
TDADcr^ ( c 1 Sample OD532nm-Blank 
TBARS Conc. of Sample 
Slope of Standard Curve 
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2.4.3 Vascular Reactivity Studies 
Aorta Isolation and Mounting 
Tested rats were sacrificed by cervical dislocation. 
Blood was drained from abdominal vein using 10ml 
syringe with 22G needle to prevent excessive blood clot /Hooks 
bin aorta. Thoracic aorta was isolated and kept in | / 
gassed ice cold-Krebs solution. Fat and connective \| y ^ A o r t a 
V V ^ Ring 
tissues were trimmed away and the aorta was divided \ _ _ Krebs 
Soln 
into 8-10 rings of length 2-3mm. The aorta ring was ^. , , � ^ 
Fig. 2.2 Setup of aorta ring 
mounted between 2 hooks and kept in the organ bath organ bath 
(Fig 2.2). The organ bath was filled with Krebs solution, kept at 37�C and gassed with 
95% O2/5% CO2. The aorta ring was equilibrated for 5 minutes. The tension of the 
aorta ring was adjusted by 3 times to 1.5g as baseline tension, and Krebs solution was 
replaced before each adjustment, with 8ml of Krebs solution was added to before last 
adjustment (Chan, 2006, Woodman and Boujaoude, 2004). 
Integrity and Function of Aorta Ring 
To confirm the integrity of the aorta ring, the contraction and relaxation of it was 
tested. To induce contraction, 2.4 i^l of lmM (R)-(-)-phenylephrine hydrochloride (Phe) 
(final conc. = 0.3 i^M) was added, and incubated for 30 minutes to induce plateau 
vasoconstriction. After incubation, 2.4 i^l of lmM acetylcholine chloride (ACh) (final 
conc. = 0.3 i^M) was added, and incubated for 5 minutes to induce 
endothelial-dependent vasodilation. Those aorta rings, with 80% or more relaxation 
compared to the baseline tension and plateau contraction tension, were regarded as 
possessing intact endothelium and were accepted for further drug test (Iizuka, et al., 
2006, Woodman and Boujaoude, 2004). Aorta rings were then washed with Krebs 
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solution for 3 times and equilibrated for 20 minutes. After that, the aorta rings were 
adjusted to baseline tension. 
DG Extract-induced Vasodilation 
Firstly, 1.2 i^l of 100^M U46619 (final conc. = 15nM) was added, and incubated 
for 30 minutes to induce plateau vasoconstriction. DG extract was dissolved in Krebs 
solution. After incubation, 2, 1，0.5, and 0.25mg/ml of DG extracts were added into 
the organ baths, and the tension was recorded by MacLab data acquisition system 
through Grass force-displacement transducers FT-03E (ADInstmments, Sydney, 
Australia) for 2 hours. The tension data were analyzed and exported by LabChart 7 
Reader. Function of the DG extract was represented by percentage of relaxation after 
the addition of DG extract, which was calculated using the following formula: 
Plateau tension - Minimum tension after relaxation 
% of relaxation 
Plateau tension -Baseline tension 
Relaxation curve was plotted by % of relaxation over concentration of DG extract 
added. 
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2.5 Statistical Analysis 
The verifications of inhibitory effect of the inhibitors were performed by 
Student's t-test or Mann-Whitney test, depending on the distribution of data. Multiple 
groups of parameters, such as systolic blood pressure, plasma lipid profile, plasma 
glucose concentration, TBARS concentration, intima-media ratio and vasodilation 
effect of DG extract, were compared with no treatment group by ANOVA (followed 
by post-hoc Dunnett test) or Kruskal-Wallis test (followed by post-hoc Dunns test), 
depending on the distribution of data. 
All statistical analyses were performed using GraphPad Prism version 5.0 for 
Windows (GraphPad Software Inc., California, USA). The data were expressed as 
mean 士 standard error of the mean (SEM). A value of p < 0.05 was considered 
statistically significant. 
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Chapter 3 
Anti-hypertensive Studies of Danshen-Gegen Formula on Rat 
3.1 Introduction 
3.1.1 In vivo Anti-Hypertensive Studies 
From the previous study by colleagues in our laboratory, Danshen and Gegen 
(Radix Puerariae thomsonii) compound formula was found to have vasodilative effect 
(Chan, 2006). Based on that finding, present study aims to investigate the underlying 
mechanisms of vasodilation. However, Radix Puerariae thomsonii was replaced by 
Radix Puerariae lobatae in the formula in the present study due to the higher content 
of components such as daidzein, daidzin and puerarin which have been previously 
shown to possess vasodilative activities (Chan, 2006). Therefore, before investigation 
of vasodilation mechanisms, the vasodilative effect of new DG extract, with the use of 
Radix Puerariae lobatae as Gegen, on rats must be confirmed. Two dosages of DG 
extract (90.2mg/kg and 300mg/kg per day) were tested, which are rat equivalent dose 
of the new and old clinical trial, respectively (see section 1.2.4.4). Blood pressure 
would be used as the parameter to determine the effectiveness of DG extract. 
Raloxifene was chosen as the positive control. The dose of 6.2mg/kg was shown 
to have blood pressure lowering effect on SHR rats (Chan et cd., 2007). It is a 
selective estrogen receptor modulators (SERMs) that inhibits vasoconstriction (Pavo 
et al., 2000) and potentiates vasodilation, which functions by (1) increasing basal NO 
release; (2) reducing vascular smooth muscle tone; and (3) improving the effect of 
NO on vascular smooth muscle in SHR (Chan et al., 2007; Chan et aL, 2010). 
Raloxifene was also found to have cholesterol lowering effect in other studies 
(Lundeen, et al.’ 1997). The dose of raloxifene was converted from daily dose of 
60mg to the human equivalent dose of lmg/kg using the same formula (see section 
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1.2.4.4). Therefore, daily dose of 6.2mg/kg of raloxifene was given to the SHR rats in 
our study. 
3.1.1.1 Spontaneously Hypertensive Rat (SHR) 
Spontaneously hypertensive rat (SHR) is a strain of inbred rat that would develop 
hypertension from 5-6 weeks old. The blood pressure would increase from 120 to 
150mmHg at 5-6 weeks old to between 180 to 200 mmHg in about 14 weeks old adult 
(Okamoto, et al., 1966). The strain was generated by mating a male Wistar rat with 
spontaneous hypertension with a female Wistar rat with a blood pressure slightly over 
the average. The spontaneous hypertensive offspring was selected to mate and repeat 
for six generations. The offspring would then have nearly 100% chance to have 
spontaneous hypertension. However, SHR was still genetically matched with WKY 
rat (Okamoto and Aoki, 1963). These factors made SHR to be a very reliable subject 
to study with an easily obtainable normotensive control. 
At the older age of 40 to 50 weeks, the SHR would develop cardiovascular 
disease character, such hypertrophy of heart and blood vessels. Some were even prone 
to stroke (Kundu and Rao, 2008). 
SHR was chosen instead of other hypertensive models (e.g. angiotensin-induced 
hypertensive rat or Dahl salt-sensitive hypertensive rat; more details to be found in 
section 5.2) since its hypertension occurs naturally and no extra manipulation is 
required. The fact that if manipulation is introduced, such as the use of injection or 
oral gavage of other drugs to induce hypertension, this will produce stress to the 
animals (i.e. may affect the blood pressure), and the potential of drug interactions with 
DG extract is also unknown. 
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3.1.1.2 Tail-cuff Blood Pressure Measurement 
In the experiment, tail-cuff blood pressure measurement was used. A tail-cuff 
was used to occlude the blood flow. Another non-invasive blood pressure sensor cuff 
was placed distal to the occlusion-cuff. There are mainly three types of sensor-cuff: 
photoplethysmography, piezoplethysmography and Volume Pressure Recording 
(VPR). Photoplethysmography illuminates a small spot on the tail and record the first 
appearance of the pulse during deflation of the occlusion cuff or the disappearance of 
pulses during inflation of the occlusion cuff. Piezoplethysmography uses the same 
theory, but piezoelectric ceramic crystals are used instead of light. Both methods are 
very susceptible to the tail movement. Last type is VPR. The VPR method transfers 
the pressure from the cuff to the sensor, which reflects the tail blood volume change. 
Appearance and disappearance of pulse would cause the tail blood volume varies. 
Thus, the blood pressure is deduced (Malkoff, 2005). 
Direct blood pressure measurement provides most accurate results. However, it 
involves surgical procedures, which cause a relatively high morbidity and is very 
undesirable for our long term animal studies. 
Therefore, in our present study, non-invasive tail-cuff blood pressure 
measurement using VPR method was selected, mainly due to the advantages of: (1) 
non-invasive but comparable accuracy to direct blood pressure measurement; (2) 
more accurate, less stress and less easily disturbed than photoplethysmography and 
piezoplethysmography; and (3) 6 Channels in one test making measurement on large 
number of rats become possible (Malkoff, 2005). 
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3.1.2 Detailed Underlying Mechanistic Studies 
Danshen-Gegen (7:3) formula was demonstrated to have anti-hypertensive effect 
on SHR rats. However, the underlying mechanism is unknown. Vasodilation may be 
one of the underlying causes for the lowered blood pressure. Therefore, aorta rings 
were used to investigate the effect of DG extract on vasodilation. Aorta, like other 
blood vessels, consist of a thick layer of smooth muscle cells (SMC) and a single 
layer of endothelial cells. In normal vasodilation, vasodilators would stimulate 
endothelium to produce signals, in form of nitric oxide (NfO) (Ignarro, et al., 1987) or 
prostacyclin (PGI2), etc. These signals would act in enzyme cascades on SMC, 
causing the dephosphorylation of myosin and detachment of myosin from actin. Thus, 
the smooth muscle would relax and cause vasodilation. 
Exogenous chemicals may stimulate endothelium to modify the production of 
NO or PGI2. They may also act on the potassium channels directly, causing the 
hyperpolarization of SMC and cause vasodilation directly. 
3.1.2.1 Nitric Oxide-mediated Vasodilation 
L-arginine is converted to nitric oxide OSfO) by nitric oxide synthase (NOS) 
(Bredt and Snyder, 1990). NO serves many different functions, like inhibiting platelet 
aggregation (Mellion, et al., 1981) and leukocyte adhesion. However, NO is also 
released by phagocytes as weapons (Hibbs, et al., 1987). During ischemic reperfusion 
process, NO would react with superoxides to form peroxynitrite, which is responsible 
for oxidative damage of the tissue (Szabo, 1996). NO is mainly produced by three 
isoforms of NOS: endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal 
NOS (nNOS). 
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eNOS is the predominant NOS within endothelial cell. Upon stimulation, 
L-arginine is converted to nitric oxide by eNOS (Rees, et al., 1989). NO released 
from the endothelium would diffuse to the SMC and activates guanylate cyclase (GC) 
to produce cyclic GMP (cGMP) (Gruetter, et a!., 1979). The increased cGMP level 
would activate more protein kinase G (PKG) (Fig 3.1). PKG phosphorylates and 
activates myosin light chain phosphatase (MLCP) (Murphy and Walker, 1998). MLCP 
catalyzes the dephosphorylation of myosin light chain, which cause myosin detaches 
from actin. The SMC relaxes and causes vasodilation. 
3.1.2.2 Prostacyclin-mediated Vasodilation 
In endothelial cell, cyclooxygenase converts arachidonic acid to prostaglandin H2 
(PGH2) (MacIntyre, et al.’ 1978). PGH2 is converted to prostacyclin (PGI2), which is 
released and binds to the G-protein coupled receptor on SMC. This causes the 
activation of adenylate cyclase and the increased production of cyclic AMP (cAMP) 
(Tanaka, et al., 2004). The increased cAMP would activate protein kinase A (PKA) 
(Fig 3.1) (Haynes, et al, 1992). PKA phosphorylates and inactivates myosin light 
chain kinase (MLCK) (de Lanerolle, et al., 1984, Somlyo and Somlyo, 2003). The 
myosin light chain kinase is responsible for phosphorylation of myosin to bind with 
actin, which is the cause of vasoconstriction. Reduced amount of active myosin light 
chain kinase can reduce vasoconstriction and make the vessels to dilate. 
3.1.2.3 Hyperpolarization-mediated Vasodilation 
Hyperpolarization happens to change the membrane potential to be more 
negative. In vascular SMC, potassium (K+) channels are mainly responsible for that. 
The opening ofK+ channels causes an efflux of potassium ions. This event is followed 
by the closure of voltage-dependent calcium channels. The entry of calcium ions is 
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reduced and the intracellular calcium is reduced. Vasodilation is the final result. 
Tetraethylammonium is the commonly used non-selective blocker for potassium 
channels. Four different types of potassium channels involved would be discussed 
below: 
Inward Rectifier K+ Channels (Kir channels) 
Kir channels have mainly 2 possible functions. The first one is the maintenance 
of resting potential of the membrane (Park, et al, 2007). The second one is the 
activation in response to the moderate increase in extracellular K+ concentration, to 
cause vasodilation (Chrissobolis, et al, 2000). Kir channels allow a large inward 
current to pass the charge into the cell, but only allow a small outward current. 
Barium salts are specific blockers to this type of channel (Fig 3.1) ^vfelson and 
Quayle, 1995). 
Voltage-dependent K+ Channels (Kv channels) 
Kv channels open in response to membrane depolarization, allowing the efflux of 
K+ p^elson and Quayle, 1995). This causes the repolarization of membrane to retum 
to the resting potential. 4-Aminopyridine is the blocker that targets this channel 
CNelson and Quayle, 1995), with little inhibition on KAip channels (Fig 3.1). 
Large-conductance Ca^^-activated K+ Channels (BKca channels) 
BKca channels can be activated by both membrane depolarization and change in 
intracellular Ca^ ^ to maintain membrane potential. Its function includes counteracting 
the pressure- or chemical-induced depolarization and vasoconstriction (Brayden and 
Nelson, 1992, Tanaka, et al., 2004). Iberiotoxin and charybdotoxin are used as 
blockers of this type of channels (Brayden and Nelson, 1992). However, iberiotoxin is 
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more specific, while charybdotoxin may also block Kv channels and intermediate 
conductance Ca^^-activated K+ channels (Fig 3.1). 
ATP-sensitive K+ Channels (KAXP channels) 
KATP channels are found in cardiac muscle and vascular smooth muscle (Fujita 
and Kurachi, 2000). Blockage of KAip channels cause depolarization and 
vasoconstriction. KAip channels activation occur mainly during disease state, which 
leads to vasodilation (Ko, et al.’ 2008). Glibenclamide is one of the most commonly 
used blocker ofKAip channels (Fig 3.1) (Nelson and Quayle, 1995). 
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Fig 3.1 Vasodilation mechanisms and involvements of inhibitors or blockers. 
Black arrows are the main pathways and red blunt lines are the action sites of 
inhibitors or blockers (Modified from Ko et aL, 2008) 
3.1.2.4 Endothelium-dependent/-independent Vasodilation 
Apart from the involvements in different pathways, the vasodilator can act 
with/without endothelium. Intrinsically, vasodilation undergoes the whole 
NO-mediated/prostacyclin-mediated vasodilation pathway and then causes the 
hyperpolization and relaxation. However, the extrinsic vasodilator may directly act on 
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the smooth muscle cells. Sodium nitroprusside (SNP), a NO-donor, can directly 
activate guanylate cyclase in SMC and cause vasodilation (Hayashi and Hester, 2010, 
Taylor, et al., 1988). A number of vasodilative Chinese herbs acting on potassium 
channels are also endothelium-independent (Pan, et al, 2008, Xia, et al, 2008). 
Therefore, determination of endothelium dependence of DG extract can help 
identifying its mode of action. 
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3.1.3 Long Term Underlying Mechanistic Studies 
The effect of long term oral intake of DG extract on aorta rings, which mimics 
the real situation in human, is still unknown. As a follow-up of previous parts, 
Danshen-Gegen 7:3 formula is able to induce vasodilation on isolated aorta rings. The 
SHR rats model would be applied again. To coherent with the methods in section 
3.1.1, the SHR rats used are 14 weeks old, which already have hypertension. DG 
extract treatment of 1 month is already able to lower the blood pressure. Aorta rings 
are isolated and tested as in section 3.1.2. In order to test the effects ofDG extract that 
were orally taken, a serial dose of acetylcholine replaces the direct addition of DG 
extract to induce vasodilation. By comparing the acetylcholine-induced relaxation 
curve between different groups, the long term effect of DG extract on aorta ring can 
be shown. The relaxation curve reflects DG extract ability to potentiate vasodilation, 
while the contractile force reflects the vasoconstriction and stiffness of the aorta. 
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3.2 Methods 
3.2.1 In vivo Anti-Hypertensive Studies 
Animals, Diet and Treatment 
Male SHR rats of 6 weeks-old and 14 weeks-old were used for the preventive 
and therapeutic studies of the effect of DG extract, respectively. The rats were divided 
into 4 groups, which were intragastrically-fed (using metal intragastric feeding tube) 
daily with either distilled water (negative control), 6.2mg/kg raloxifene (positive 
control), 90.2mg/kg or 300mg/kg ofDG extract dissolved in distilled water. WKY rats 
of same age were used as normal control and were fed with distilled water in same 
manner (Table 3.1). The rats were given at libitum assess to food and water. 
Table 3.1 Treatment and sample size of each group in the preventive and 
therapeutic studies of DG extract on hypertension 
Rats Treatments Sample size in Sample size in 
Preventive study Therapeutic study = = = =j — = 
WKY Water (4ml/kg), as negative control 6 6 
SHR Water (4ml/kg), as negative control 6 6 
SHR 90.2mg/kg DG extract in water 6 6 
(4ml/kg) 
SHR 300mg/kg DG extract in water 6 6 
(4ml/kg) 
SHR 6.2mg/kg Raloxifene in water 6 6 
(4ml/kg), as positive control 
Blood Pressure Measurement 
Systolic blood pressure measurement was carried out bi-weekly from 6 
(preventive study) or 14 weeks (therapeutic study) for 12 weeks, according to 
protocol in 2.4.1. The average systolic blood pressure of each group was plotted 
against time. 
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Sampling of Animal Tissue 
After 12 weeks of treatment, the rats were sacrificed by cervical dislocation. All 
rats were fasted for 12 hours before blood collection. Blood sample was collected 
from abdominal vein and plasma was prepared for total cholesterol, triglyceride and 
glucose measurements as stated in protocol 2.4.2. 
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3.2.2 Detailed Underlying Mechanistic Studies 
Animals and Sampling of Aorta 
Male SD rats of 295 - 305g were sacrificed by cervical dislocation. Sampling 
was done according to "Aorta Isolation and Mounting" of section 2.4.3. 
Mechanistic Study 
Preparation and confirmation of function of aorta was done according to "Aorta 
Isolation and Mounting" and "Integrity and Function of Aorta Ring" of section 2.4.3. 
The experimental protocol was similar to "DG extract-induced vasodilation" of 
section 2.4.3, except that different concentrations of various blockers (Table 3.2) were 
added and incubated for additional 30 minutes (Park, et aI., 2003) before addition of 
U 4 6 6 1 9 . The doses of blockers, vasoconstrictors (Phe or U46619) and vasodilator 
(ACh) used in the present study were based on previous literatures (Park, et al.’ 2003; 
Ko, et al, 2008). U46619 (9,11 -Dideoxy-11 a,9a-epoxymethanoprostaglandin F2a) is a 
prostaglandin H2-anal0gue and has similar biological activity as thromboxane A2, 
which can cause vasoconstriction (Coleman, et al., 1981). ACh is the neurotransmitter 
in both CNS and PNS. In vascular endothelial cells, it acts on acetylcholine 
muscarinic M3 receptor, which leads to increased the synthesis of NO and PGI2 and 
causes vasodilation (Spence, et cd., 2004). On the other hand, Phe is an 
alpha-1 (al) adrenergic receptor agonist. Alpha-1 adrenergic receptor is responsible 
for the fight-or-flight response, which cause vasoconstriction in arteries when 
stimulated (Varma and Deng, 2000). 
Relaxation curves of DG extract treatments with different blockers were 
compared to the relaxation curve of DG extract treatment alone. 
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For endothelium-independent vasodilation, denudation was performed by gentle 
rubbing of aorta ring against a wooden toothpick. The denudation was confirmed by 
the inability of ACh to induce vasodilation, as ACh-induced vasodilation is 
endothelium-dependent. 
Table 3.2 The various blockers used in the mechanistic studies {ex vivo) 
Blockers Full Name Properties Concentrations Vasoconstrictors 
used used 
No)-Nitro-L-arginine Non-specific nitric 
L-NAME methyl ester oxide synthase lOO i^M U46619 
hydrochloride inhibitor 
Non-specific 
Indomethacin cyclooxygenase lO i^M U46619 
inhibitor 
Tetraethylammon Non-selective K 
TEA lOmM U46619 
-ium chloride channels blocker 
BaCl2 Barium chloride Kir channels lOO i^M U46619 
Kv channels 
4-AP 4-aminopyridine lmM U46619 
blocker 
BKca channels 
IbTX Iberiotoxin 100nM U46619 
blocker 
KATP channels 
Glibenclamide — lO i^M Phenylephrine 
blocker 
^^^^^^^^^^^^^^^^^^^^^^^=^^^^=^^=^^^^^=^^^=^^^=:S^^ ^=S^=S^^BSSS^ 
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3.2.3 Long Term Underlying Mechanistic Studies 
Animals, Diet and Treatment 
Male SHR rats of 14 weeks-old were purchased and kept in the University 
Centralized Science Laboratory Building. Diet and treatment of the SHR rats were the 
same as that described in section 3.12 (Table 3.3). 
Table 3.3 Treatment and sample size of each group in the mechanistic study of 
DG extract on hypertension 
Rats Treatments Sample size 
WKY Water (4ml/kg), as negative control 6 
SHR Water (4ml/kg), as negative control 6 
SHR 90.2mg/kg DG extract in water (4ml/kg) 6 
SHR 30Qmg/kg DG extract in water (4ml/kg) 6 
SHR 6.2mg/kg Raloxifene in water (4ml/kg), 6 
as positive control 
Blood Pressure Measurement 
Blood pressure measurement was carried out at 14^ ^ week (Before treatments) 
and 18th week (after treatments), according to protocol in section 2.4.1. 
Sampling of Aorta 
After 4 weeks of treatment, the rats were sacrificed by cervical dislocation. 
Sampling was done according to "Aorta Isolation and Mounting" ofsection 2.4.3. 
Mechanistic Study 
Preparation and confirmation of function of aorta was done according to “Aorta 
Isolation and Mounting" and "Integrity and Function ofAorta Ring" ofsection 2.4.3. 
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Different concentration ofvarious blockers (Table 3.4) were added and incubated 
for 30 minutes. 
Table 3.4 The various blockers used in the mechanistic studies (in vivo 
confirmation) 
Blockers Full Name Properties Concentrations Vasocontrictors 
used used 
No)-Nitro-L-arginine Non-specific nitric 
L-NAME methyl ester oxide synthase lOO i^M Phenylephrine 
hydrochloride inhibitor 
Non-specific 
Indomethacin cyclooxgenase lO i^M Phenylephrine 
inhibitor 
Tetraethylammon Non-selective K 
TEA lOmM Phenylephrine 
-ium chloride channel blocker 
2.4 i^l of lmM Phe (fmal conc. = 0 . 3 _ was added, and incubated for additional 
30 minutes to induce plateau vasoconstriction. After incubation, 6 concentrations of 
ACh ranging from 10"^  to 10'^ M were added into the organ baths in 5 minute-intervals, 
and the tension was recorded by MacLab data acquisition system through Grass 
force-displacement transducers FT-03E (ADInstruments, Sydney, Australia). 
Percentages of relaxation after each addition of ACh were calculated using following 
formula: 
Plateau tension - Minimum tension before next ACh addition | 
% of relaxation — ： ~ : ：~： | 
Plateau tension -Baseline tension | 
- 5 4 - -
Chapter 4 Anti-atherosclerosis Studies ofDanshen-Gegen Formula on Rabbits 
The contractile force after addition of Phe was calculated using following 
formula: 
Contractile force = Plateau tension - Minimum tension before Phe addition 
The relaxation curves with/without blocker were compared. The maximum 
contractile force was recorded as the difference between plateau tension and baseline 
tension. The differences in relaxation curves among different groups were also 
compared. 
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3.2.4 Statistical analysis 
In vivo Anti-Hypertensive Studies 
In systolic blood pressure and weight measurement, ANOVA was used for 
analysis. The data for WKY group were compared with that of untreated SHR group, 
while the data for the treatment groups were compared with that of untreated SHR. 
In blood profile assays, student's t-test was used for comparison between WKY 
group and untreated SHR group. ANOVA was used to compare the data for the 
treatment groups with that of untreated SHR. 
Detailed Underlying Mechanistic Studies 
In the study of the effect of Danshen-Gegen 7:3 water extract on dilation of 
intact rat aorta rings, all treatment groups were compared with the Kreb's group using 
ANOVA. In assays using denuded aorta, or with inhibitors/blockers treated, the data 
of denuded or inhibitors/blockers treated groups were compared with the intact, 
untreated aorta with same dose ofDG extract added, using student's t-test. 
Long Term Underlying Mechanistic Studies 
In systolic blood pressure measurement and vasodilation assay using increasing 
dose of ACh, ANOVA was used for analysis. The data for WKY group were compared 
with that of untreated SHR group, while the data for the treatment groups were 
compared with that of untreated SHR. 
In contractile force assay and vasodilation assay using single dose of ACh, 
student's t-test was used for comparison between WKY group and untreated SHR 
group. ANOVA was used to compare the data for the treatment groups with that of 
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untreated SHR. 
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3.3 Results 
3.3.1 In vivo Anti-Hypertensive Studies 
3.3.1.1 Preventive Effect in Hypertension 
Danshen-Gegen 7:3 water extract was tested for the preventive effect in 
hypertension in SHR rats of 6 weeks old, in which hypertension have not yet been 
developed. In Fig 3.2, the SHR rats had an increasing trend of systolic blood pressure 
from 6 weeks onwards. SHR rats reached a significantly higher systolic blood 
pressure (-200mmHg) starting from week 10，comparing with WKY rats. Treatments 
of 6.2mg/kg of raloxifene and 90.2mg/kg and 300mg/kg of DG extract could 
significantly lower the plateau systolic blood pressure to about 180mmHg. The 
anti-hypertensive effect of 90.2mg/kg and 300mg/kg ofDG extract had no significant 
difference. 
Regarding other plasma parameters, SHR rats had significantly lower plasma 
triglyceride (Fig 3.3 b). Comparing with SHR rats without treatments, 6.2mg/kg of 
raloxifene could significantly lower the plasma total cholesterol (Fig 3.3 a). There was 
no significant difference among groups in plasma glucose level (Fig 3.4).The weights 
ofthe rats have no significant difference among groups (Fig 3.5). 
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Fig 3.2 Preventive Effect of Danshen-Gegen 7:3 water extract on hypertension in 
SHR rats. All extracts/drug/water were administered daily by oral gavage. All data 
are presented in mean 土 SEM (n=6). ANOVA was used for statistical analysis. WKY 
vs SHR, # p < 0.05; SHR vs treatment groups, * p < 0.05. 
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Fig 3.3 Effect of Danshen-Gegen 7:3 water extract on plasma lipid level in SHR 
rats (Preventive Study). (a)Plasma total cholesterol level; (b) Plasma triglyceride 
level. SHR group is compared with WKY groups. All treatment groups are compared 
with SHR group. All data are presented in mean 士 SEM (n=6). WKY vs SHR using 
student's t-test, # p < 0.05; SHR vs treatment groups using ANOVA, * p < 0.05. 
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Fig 3.4 Effect of Danshen-Gegen 7:3 water extract on plasma glucose level in 
SHR rats (Preventive Study). All data do not show a significant difference. All data 
are presented in mean 土 SEM (n=6). WKY vs SHR using student's t-test, # p < 0.05; 
SHR vs treatment groups using ANOVA, * p < 0.05. 
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Fig 3.5 Effect of Danshen-Gegen 7:3 water extract on the weight of SHR rats 
(Preventive Study). All data do not show a significant difference. All data are 
presented in mean 土 SEM (n=6). ANOVA was used for statistical analysis. • p < 
0.05. 
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3.3.1.2 Therapeutic Effect in Hypertension 
Danshen-Gegen 7:3 water extract was tested for the therapeutic effect 
against hypertension in SHR rats of 14 weeks old, during which hypertension was 
developed. In Fig 3.6, from weeks 14，the SHR rats had significantly higher systolic 
blood pressure (-200mmHg), compared with WKY rats. After treatments, 6.2mg/kg 
of raloxifene and 90.2mg/kg and 300mg/kg of DG extract could significantly lower 
the plateau systolic blood pressure to about 180mmHg. Again, no dose dependent 
response was observed between 90.2mg/kg and 300mg/kg ofDG extract treatments. 
Regarding other plasma parameters, SHR rats had significantly lower cholesterol 
and triglyceride (Fig 3.7). Comparing with SHR rats without treatments, 6.2mg/kg of 
raloxifene and 90.2mg/kg of DG extract could significantly lower the plasma total 
cholesterol (Fig 3.7 a). There was no significant difference among groups in plasma 
glucose level (Fig 3.8). The weights of the rats have no significant difference among 
groups (Fig 3.9). 
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Fig 3.6 Therapeutic effect of Danshen-Gegen 7:3 water extract on hypertension 
in SHR rats. All extracts/drug/water were administered daily by oral gavage. All data 
are presented in mean 土 SEM (n=6). ANOVA was used for statistical analysis. WKY 
vs SHR, # p < 0.05; SHR vs treatment groups, * p < 0.05. 
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Fig 3.7 Effect of Danshen-Gegen 7:3 water extract on plasma lipid level in SHR 
rats (Therapeutic Study). (a)Plasma total cholesterol level (b) Plasma triglyceride 
level. SHR group is compared with WKY groups. All treatment groups are compared 
with SHR group. All data are presented in mean 土 SEM (n=6). ANOVA was used for 
statistical analysis. WKY vs SHR using student's t-test, # p < 0.05; SHR vs treatment 
groups using ANOVA, * p < 0.05. 
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Fig 3.8 Effect of Danshen-Gegen 7:3 water extract on plasma glucose level in 
SHR rats (Therapeutic Study). All data do not show a significant difference. All 
data are presented in mean 土 SEM (n=6). WKY vs SHR using student's t-test, # p < 
0.05; SHR vs treatment groups using ANOVA, * p < 0.05. 
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Fig 3.9 Effect of Danshen-Gegen 7:3 water extract on the weight of SHR rats 
(Therapeutic Study). All data do not show a significant difference. All data are 
presented in mean 土 SEM (n=6). ANOVA was used for statistical analysis. * p < 
0.05. 
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3.3.2 Detailed Underlying Mechanistic Studies 
3.3.2.1 DG extract-induced Vasodilation 
DG extract was tested for the vasodilative effect on aorta rings isolated from SD 
rats, which were normotensive. In Fig 3.10, aorta rings without any DG extract added 
had 26% of relaxation. With 0.25 mg/ml of DG extract added, the percentage of 
relaxation was 27%, which was similar to that without DG treatment. With addition of 
0.5 mg/ml ofDG extract, the relaxation percentage was 46% and showed a significant 
relaxation. The addition of 1 and 2 mg/ml DG extract caused a 96% and 110% 
relaxation, respectively. These doses of DG extract were used in the vasodilation 
study, as 0.25mg/ml DG extract induced no relaxation and 2mg/ml of DG extract 
induced a full relaxation. This ensured the full coverage of different relaxation extents 
in our test. 
160n 
* * * 
� L i i 
> ' / / / / yyv, 
Fig 3.10 Effect of Danshen-Gegen extract on dilation of intact rat aorta rings. All 
data are presented in mean + SEM (n=7-12). ANOVA was used for statistical analysis. 
**p<0.01;***p<0.001. 
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3.3.2.2 Endothelium-independent Vasodilation 
The endothelium of aorta rings were denuded by gentle rubbing against a 
wooden toothpick to remove endothelium. The denuded aorta rings were tested and 
compared against the intact ones. In Fig 3.11，aorta rings without any DG extract 
added had 19% ofrelaxation. With 0.25, 0.5, 1 and 2 mg/ml ofDG extract added, the 
percentage of relaxation was 32%, 42%, 94% and 113% relaxation, respectively. The 
relaxation was not significantly different from intact aorta. 
150%i 
國 Denuded Aorta 
政 lntactAorta 
1 1 � � % - 諭 B | ; 
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/ /夕、夕、〜 
Fig 3.11 Effect of Danshen-Gegen extract on dilation of denuded rat aorta rings. 
All data are presented in mean 土 SEM (n=4-12). Student's t-test was used for 
statistical analysis of each pair. * p < 0.05. 
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3.3.2.3 Nitric Oxide-mediated Vasodilation 
The intact aorta rings were treated with L-NAME before addition of DG extract. 
The treated aorta rings were tested and compared against the untreated ones. In Fig 
3.12, aorta rings without any DG extract added had 24% of relaxation. With 0.25, 0.5, 
1 and 2 mg/ml of DG extract added, the percentage of relaxation was 27%, 82%, 99% 
and 110% relaxation, respectively. The relaxation was not significantly different from 
intact aorta. 
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Fig 3.12 Effect of L-NAME on DG extract-induced vasodilation on intact rat 
aorta rings. All data are presented in mean 土 SEM (n=3-12). Student's t-test was 
used for statistical analysis of each pair. * p < 0.05. 
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3.3.2.4 Prostacyclin-mediated Vasodilation 
The intact aorta rings were treated with indomethacin before addition of DG 
extract. The treated aorta rings were tested and compared against the untreated ones. 
In Fig 3.13, aorta rings without any DG extract added had 34% of relaxation. With 
0.25, 0.5, 1 and 2 mg/ml ofDG extract added, the percentage of relaxation was 35%, 
60%, 97% and 111% relaxation, respectively. The relaxation was not significantly 
different from intact aorta, except the relaxation with indomethacin was significantly 
higher at 0.25mg/ml DG extract. 
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Fig 3.13 Effect of indomethacin on DG extract-induced vasodilation on intact rat 
aorta rings. All data are presented in mean 土 SEM (n=4-12). Student's t-test was 
used for statistical analysis of each pair. * p < 0.05. 
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3.3.2.5 Hyperpolarization-mediated Vasodilation 
The intact aorta rings were treated with TEA, BaCl2, 4-AP, IbTX or 
glibencamide before addition of DG extract. The treated aorta rings were tested and 
compared against the untreated ones. In Fig 3.14, aorta rings were treated with TEA, a 
non-selective potassium channel blocker. Aorta rings without any DG extract added 
exhibited 29% of relaxation. With 0.25, 0.5, 1 and 2 mg/ml of DG extract added, the 
percentage of relaxation was 32%, 47%, 58% and 104% relaxation, respectively. The 
relaxation with addition of lmg/ml DG extract was significantly lower with TEA. 
In Fig 3.15，aorta rings were treated with BaCl2, a Kir channel blocker. Aorta 
rings without any DG extract added had 31% of relaxation. With 0.25, 0.5，1 and 2 
mg/ml of DG extract added, the percentage of relaxation was 29%, 31%, 41% and 
95% relaxation, respectively. The relaxation with addition of lmg/ml DG extract was 
significantly lower with BaCl2. 
In Fig 3.16, aorta rings were treated with 4-AP, a voltage-dependent potassium 
channel blocker. Aorta rings without any DG extract added had 27% of relaxation. 
With 0.25, 0.5, 1 and 2 mg/ml of DG extract added, the percentage of relaxation was 
35%, 38%, 64% and 106% relaxation, respectively. The relaxation with addition of 
lmg/ml DG extract was significantly lower with 4-AP. 
In Fig 3.17, aorta rings were treated with IbTX, a BKca channel blocker. Aorta 
rings without any DG extract added had 41% of relaxation. With 0.25, 0.5，1 and 2 
mg/ml of DG extract added, the percentage of relaxation was 37%, 47%, 92% and 
99% relaxation, respectively. The relaxation without DG extract added with addition 
of0.25mg/ml DG extract was significantly higher with IbTX. 
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In Fig 3.18, aorta rings were treated with Glibencamide, a KAip channel blocker. 
Aorta rings without any DG extract added had 14% of relaxation. With 0.25, 0.5, 1 
and 2 mg/ml ofDG extract added, the percentage of relaxation was 14%, 23%, 19% 
and 58% relaxation, respectively. The relaxations of all groups were significantly 
lower with addition of Glibencamide. Severe inhibition was shown in the DG extract 
dosages of 1 and 2mg/ml. 
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Fig 3.14 Effect of tetraethylammonium (TEA) on DG extract-induced 
vasodilation on intact rat aorta rings. All data are presented in mean ± SEM 
(n=3-12). Student's t-test was used for statistical analysis of each pair. *** p < 0.001. 
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Fig 3.15 Effect of barium chloride (BaCh) on DG extract-induced vasodilation on 
intact rat aorta rings. All data are presented in mean 土 SEM (n=4-12). Student's 
t-test was used for statistical analysis of each pair. *** p < 0.001. 
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Fig 3.16 Effect of 4-aminopyridine (4-AP) on DG extract-induced vasodilation on 
intact rat aorta rings. All data are presented in mean 土 SEM (n=4-12). Student's 
t-test was used for statistical analysis of each pair. *** p < 0.001. 
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Fig 3.17 Effect of iberiotoxin (IbTX) on DG extract-induced vasodilation on 
intact rat aorta rings. All data are presented in mean 土 SEM (n=4-12). Student's 
t-test was used for statistical analysis of each pair. *• p < 0.01; **• p < 0.001. 
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Fig 3.18 Effect of glibencamide on DG extract-induced vasodilation on intact rat 
aorta rings. All data are presented in mean 土 SEM (n=4-12). Student's t-test was 
used for statistical analysis of each pair. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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3.3.3 Long Term Underlying Mechanistic Studies 
From Fig 3.19, the initial systolic pressures for different groups of SHR rats were 
similar, while the systolic blood pressures of SHR rats were significantly higher than 
WKY rats at 14 weeks old. After 4 weeks of treatment, raloxifene, 90.2 and 300 
mg/kg of DG extract could significantly lower the systolic blood pressure comparing 
with SHR rats control. Systolic blood pressures of SHR rats remained higher than 
WKYrats. 
From Fig 3.20，DG extract- or Raloxifene-treated and untreated aorta did not 
show any significant difference in relaxation in any dosages of ACh, with or without 
addition of inhibitors of different pathway. WKY rats showed a significant less 
relaxation than SHR rats by addition of low concentration of ACh (10"^  to 10¾) in 
the absence ofblocker or with indomethacin. 
Fig 3.21 showed the maximum relaxation of aorta rings from different groups of 
rats. The relaxations of SHR rats were significantly lower than those of WKY rats for 
about 10%. The treated groups showed slight decrease in relaxation percentage. 
However, no significance was reached. Contractile force was significantly reduced 
from about 0.8g to 0.6g by Raloxifene, 300 or 90.2 mg/ml DG extract-treated groups 
when comparing with untreated SHR group (Fig. 3.22) 
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Fig 3.19 Effect of Danshen-Gegen 7:3 water extract on hypertension in SHR rats 
(Mechanistic study). All extracts/drug/water were administered daily by oral gavage. 
All data are presented in mean 土 SEM (n=6). ANOVA was used for statistical 
analysis. WKY vs SHR, # p < 0.05; SHR vs treatment groups, * p < 0.05. 
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Fig 3.20 Effect of different concentration of acetylcholine (ACh) on 
phenylephrine-contracted aorta rings. The aorta rings were (a) not treated, or 
treated (b) L-NAME, (c) indomethacin and (d) TEA. All data are presented in mean 土 
SEM (n=4-6). ANOVA was used for statistical analysis. WKY vs SHR, # p < 0.05; 
###p<0.001. 
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Fig 3.21 Maximum relaxation induced by 0.3nM acetylcholine (ACh) on 0.3jiM 
phenylephrine-contracted aorta rings. All data are presented in mean 土 SEM 
(n=4-6). ANOVA was used for statistical analysis. WKY vs SHR, # p < 0.05 
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Fig 3.22 Maximum contraction force induced by 0.3jiM phenylephrine. All data 
are presented in mean 土 SEM (n=4-6). ANOVA was used for statistical analysis. 
SHR vs treatment groups, * p < 0.05; ** p < 0.01. 
- 7 8 - -
Chapter 4 Anti-atherosclerosis Studies of Danshen-Gegen Formula on Rabbits 
3.4 Discussion 
In order to investigate the anti-hypertensive effect of DG extract, the change in 
systolic blood pressure was compared between SHR rats with and without DG 
treatments. The positive control raloxifene was used due to its effect in reducing 
blood pressure, which was validated in both preventive and therapeutic studies. The 
results were consistent with what we have mentioned in section 3.1.1 that raloxifene 
was able to reduce plasma cholesterol level but the effect was not related to 
triglyceride, glucose and weight. Preventive effect of DG extract was tested on the 
SHR rats of 6 weeks old, which were in the pre-hypertensive state. Severe 
hypertension would gradually develop in adults. The effect of DG extract on the 
development of hypertension, i.e. the ability to delay, prevent or reduce the 
hypertensive progression, was the scope we want to examine. In present study, DG 
extract was unable to delay or prevent hypertension. However, it had the ability to 
stably lower the plateau systolic blood pressure. 
Therapeutic effect of DG extract was tested on the SHR rats of 14 weeks old, 
which bear severe hypertension. The aim of study became the ability of DG extract to 
reduce blood pressure. In this study, daily administration ofDG extract caused decline 
in systolic blood pressure within 2 weeks, and no rebounce was observed in later 
weeks. 
About the lipid profile, the higher cholesterol level in the preventive study and 
the lower cholesterol level in the therapeutic study could be explained by the diumal 
cycle ofthe rat, which has higher cholesterol in early moming (6 to 8 a.m.) and lower 
in the afternoon (1 to 3 p.m.) (Rand and Quackenbush, 1965). On the other hand, the 
triglyceride levels were higher in the preventive study than those in the therapeutic 
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Study. These might be due to the individual differences in these two studies, as the 
trends were similar in both studies, except a general increase in readings for all 
groups. 
In both preventive and therapeutic studies, the blood pressure after DG extract 
treatments were similar, and no dose-dependent effect was shown. The possible 
explanation can be that the dose of DG extract was already in excess even at the low 
dose studied. Therefore, the hypotensive effects in both cases were already at 
maximum and the increase in doses could not further lower the blood pressure. For 
prevention of hypertension, a drug should be able to avoid hypertension from 
developing or slowing down the progression of hypertension. However, DG extract 
could not achieve either of them. Whilst the only effect of DG extract found was 
reducing blood pressure from -200mmHg to �180mmHg, suggesting that the effect of 
DG extract was therapeutic instead of preventive in hypertension management. After 
confirming the anti-hypertensive effect of DG extract, the next step was to identify its 
action mechanisms. As discussed before, the drug treatment of hypertension includes 
diuretics, ACE inhibitors, angiotensin receptor antagonists, calcium channel blockers, 
P-adrenergic receptor blockers, and vasodilators. These drugs are having different 
action target and mechanisms. In our study, Danshen and Gegen were found to have 
vasodilative functions. Therefore, it is highly suspected that DG extract would also act 
as a vasodilator. Thus, we evaluated the vasodilative activity in isolated aorta to 
support the DG extract-induced blood pressure alleviation in hypertensive rats. 
Vasodilators mainly act through three pathways as mentioned: nitric 
oxide-mediated, prostacyclin-mediated, or hyperpolarization- mediated vasodilation. 
The commonly used method to identify the mechanism is the vascular reactivity study. 
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Blocker or inhibitor of above pathways may change the degree of relaxation of aorta 
ring, which indicates its participation in DG extract action. 
SD rats were used instead of WKY rats in this part of the study because the 
concentrations of blockers, vasoconstrictors and vasodilators used were based on 
previous studies. Since SD rats were used in most of the previous studies and that 
different strains of rats may have different responses to the blockers, vasoconstrictors 
and vasodilators, hence SD rats were chosen in our study. 
The major findings of the present study indicate that DG extract caused full 
relaxation in rat aorta rings in a dose-dependent manner. The vasodilation was not 
affected by endothelium denudation, reflecting the effect is endothelium-independent. 
Theoretically, endothelium is responsible for the expression of eNOS and 
cyclooxygenase, which produce NO and prostaglandin H2. NO and prostaglandin I2 
are the mediator of NO-mediated or prostacyclin-mediated vasodilation. Thus, an 
endothelium-dependent vasodilation should not have NO-mediated or 
prostacyclin-mediated vasodilation involved. The results of this study show that the 
vasodilation is not abolished by L-NAME and indomethacin. That reflects DG extract 
induced vasodilation is not NO-mediated or prostacyclin-mediated, which match the 
theory. 
Other major findings are the involvement of hyperpolarization in vasodilative 
effect of DG extract, which presented by the inhibition of relaxation by a 
non-selective potassium channel blocker, TEA. The finding is reasonable as 
hyperpolarization-mediated vasodilation is endothelium independent, which is proved 
to be responsible for DG extract's action. So, individual types of potassium channels 
- 8 1 - -
Chapter 4 Anti-atherosclerosis Studies ofDanshen-Gegen Formula on Rabbits 
are investigated for their involvement. It is found that the response to lmg/ml ofDG 
extract was markedly reduced by BaCl2, 4-AP, and glibencamide, which are blockers 
of Kir channel, voltage-dependent potassium channel and KAip channel, respectively. 
However, the inhibition is recovered in high concentration of DG extract. This 
indicates that the vasodilative action ofDG extract is not a single pathway process. 
From other studies, it is found that tanshinone IU, a lipophilic active ingredient 
of Danshen, induce relaxation on rat coronary arteries and aorta, through 
NO-mediated vasodilation (Kim, et al, 2007, Wu, et aL, 2009) and KAip 
channel-related (Chan, et al” 2009) respectively. Aqueous extract of Danshen and its 
active components, Danshensu and salvianolic acid B, are able to cause relaxation in 
rat coronary arteries. The relaxation can be partially inhibited by TEA and is 
potassium channels-related. The relaxation is also tested to be related to inhibition of 
calcium channels (Lam, et al., 2007, Lam, et aL, 2006). Gegen active component, 
Daidzein, is showned to improve endothelial function in many studies (Colacurci, et 
al., 2005, Mishra, et al, 2000). Therefore, its vasodilative action is mainly described 
as NO-mediated (Mishra, et al., 2000, Vera, et al, 2005). However, daidzein is also 
found to be acting on rats cerebral basilar arteries and thoracic aorta through 
large-conductance calcium-activated potassium channels (Sun, et al., 2007, Zhang, et 
al., 2010), KiR channels and Na+/K+-ATPase (Sodium-Potassium Pump) (Woodman 
and Boujaoude, 2004). In addition, daidzein also found to be reducing the endothelial 
release of prostaglandin H2, a cyclooxygenase-derived vasoconstrictor (Vera, et al, 
2005). Vasodilative action of puerarin, another active component of Gegen, was also 
found to be involved in the large-conductance calcium-activated potassium channels 
(Sun, et al,, 2007). The above studies showed that a large variety of pathways are 
involved in the vasodilation process, and the action mechanism remains controversial. 
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As shown in Table 3.5, we observed that the findings in the present study have 
some discrepancies from our previous findings (Chan, 2006). A possible explanation 
is the difference in active components in the aqueous and ethanolic extracts. Also, the 
findings among studies differed from each other when different arteries were used 
(Chan, et cd., 2009; Kim, et al., 2007; Mishra et aL 2000; Sun, et cd., 2007; 
Woodman and Boujaoude, 2004; Wu, et al., 2009; Zhang, et al., 2010). Moreover, the 
other studies were using pure compounds in which their doses were much higher than 
the crude extract. The insufficient doses of pure compounds in the crude extract 
would also explain the absence of involvement of some pathways in our study, which 
found to be involved in other studies. The vasodilation effect of DG extract, in its 
effective dose, should act endothelium-independently through Kir channel, 
voltage-dependent potassium channel, KAip channel, and one or more mechanisms 
that were not tested in this study. The comparison is summarized in Table 3.5. 
After testing the direct effect of DG extract on rat aorta rings, the effect of 
chronic administration o f D G extract was assessed. Hypertensive, 14 weeks old SHR 
rats were orally fed with DG extract for 4 weeks. The aorta was isolated and test for 
vascular reactivity. Commonly used blockers for NO-mediated, prostacyclin-mediated 
and hyperpolarization-mediated, L-NAME, indomethacin and TEA, were added to 
test for the involvement of the pathways. 
At 14 weeks, the SHR rats were hypertensive with similar systolic blood 
pressure. The hypertension was significantly alleviated by 4 weeks of raloxifene or 
DG extract treatments. However, the isolated aorta rings of different groups shows 
similar relaxation patterns during serial addition of increasing concentrations ofACh. 
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The observation is very different from the other studies, which SHR rats show a lower 
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vascular reactivity than WKY rats (Gomez-Roso, et al., 2009, Jednakovits, et al., 
2000, Romero, et al, 2010). This possibly due to the young age of the rats, as 
generally, rats are sacrificed at 24 weeks old or more in this type of blood pressure 
measurement plus vascular reactivity test (Gomez-Roso, et al., 2009, Romero, et al., 
2010), as supported by the increase in vascular stiffness along with aging. As there 
was no observable difference between SHR rats and WKY rats, it was normal that the 
chronic intake of raloxifene or DG extract did not modify the relaxation profile of 
SHR rats. Nevertheless, NO-mediated, prostacyclin-mediated and 
hyperpolarization-mediated vasodilation are not affected either. 
As a follow-up investigation, maximum relaxation on aorta rings by single 
0.3p,M of ACh were compared, and the relaxations of SHR rats were significantly 
smaller than the WKY rats, but the difference was only about 10%. The chronic intake 
of raloxifene or DG extract has a dose-dependent trend to increase the relaxation. 
However, no significance was reached, possibly due to the small basal difference 
between relaxation of SHR rats and WKY rats. The basal difference of the other 
studies would be 30-40% (Gomez-Roso, et al., 2009; Jednakovits， et al., 2000; 
Romero, et al.,20l0). 
Carotid arteries from 1 -wk-old SHR rats exhibited narrower lumen and 
greaterintrinsic stiffness than those from their WKY and SD counterparts (Arribas, et 
aL, 2008). This characteristic may also present in adult rats. The increased stiffness 
can explain the reduced contractile force in SHR rats than WKY rats, while the 
narrower lumen maintains the high blood pressure. The contractile force was also 
smaller in SHR rats after chronic intake of raloxifene or DG extract. Deducing from 
that, raloxifene and DG extract may possibly reduce vasoconstriction, in addition to 
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its vasodilative effect. 
Conclusion 
In conclusion, this study provides experimental evidence that DG extract 
treatments reduce the systolic blood pressure of SHR rats. The reduction of systolic 
blood pressure may be contributed by the vasodilative effect of DG extract. The 
vasodilative effect of DG extract is endothelium-independent and partially mediated 
by hyperpolarization. Possibility of NO-mediated and prostacyclin-mediated 
vasodilation are eliminated. Long term treatment of DG extract have a trend of 
increasing vascular relaxation percentage, and reduce the contraction force. 
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Chapter 4 
Anti-atherosclerosis Studies of Danshen-Gegen Formula in Rabbits 
4.1 Introduction 
From our previous clinical studies (Tam, 2004), long term intake of 
Danshen-Gegen 7:3 formula showed an anti-atherosclerotic effect in human assessed 
by carotid Doppler ultrasound. In order to show morphological changes induced by 
DG extract on atherosclerosis, a rabbit model was applied. Atherosclerosis was 
induced in rabbits by a high cholesterol diet, which is also a main inducing factor in 
human situation. The treatment started once after the plaque was formed. The 
treatment aimed to test DG extract's therapeutic effect instead of preventive effect. 
This mimics the real situation of giving the medical treatment after diagnosis of 
atherosclerosis in human. DG extract was given daily by oral gavage. The dosages of 
DG extract was equivalent to IX, 3X, and 9X of the current clinical dose that is being 
used in the current clinical trial. Blood lipid profile and oxidative status were 
measured for deduction of possible underlying mechanism that causes the 
anti-atherosclerotic effect. Most importantly, the intima-media thickness, which 
reflects the extent of atherosclerosis, was shown histochemically in the aorta section 
(Boger, et al, 1998，Choe, et al, 2001). 
4.1.1 Intima-Media Thickening 
Intima-media thickening is a main morphological change on blood vessels in 
atherosclerosis (Cobble and Bale, 2010). Atherosclerosis is caused by the 
inflammatory process. A high plasma cholesterol level, especially low-density 
lipoprotein (LDL) cholesterol, can cause the formation of plaque. LDL cholesterol can 
be oxidized and become oxidized LDL cholesterol (oxLDL). On the other hand, 
endothelial cells would express more adhesion molecules that recruit leukocytes from 
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the bloodstream to the endothelium. One of the major adhesion molecules, vascular 
cell adhesion molecule-1 (VCAM-1), binds with monocytes and T-lymphocytes, 
which actively participate in initial stage of atherosclerosis. After the recruitment, the 
monocytes enter the sub-endothelial space, and differentiate into macrophages. The 
macrophages process scavenger receptors to bind and endocytose oxLDL 
continuously. The macrophages would accumulate oxLDL and subsequently fill with 
lipid droplets. This leads to the formation of foam cells. The foam cells accumulate 
under endothelium and form fatty streak, which show an initiation of intima-media 
thickening. The foam cells would release cytokines, which worsen the inflammatory 
process. As the vicious cycle continues, smooth muscle cells (SMC) migrate from the 
media to the sub-endothelial space. As the SMC proliferate, it would secrete 
extracellular matrix proteins, tuming fatty streak to a fibrous plaque. The 
intima-media thickness would increase and the lumen size is further reduced. 
Therefore, intima-media thickness can reflect the stage and extent of atherosclerosis 
(Bots, etaL, 1997). 
In worst situation, the atheroma would rapture and the content would form a 
thrombus, which travel along the bloodstream. The thrombus would block the blood 
flow of small vessels, leading to an infarction of the destination organ. This is also the 
main clinical complication seen in atherosclerosis. 
4.1.2 Effect of High Cholesterol Diet in Rabbit 
New Zealand White rabbits were chosen to be the subject of our study. From 
previous researches, a few days of high cholesterol diet can induce 
hypercholesterolaemia in rabbits, but not in rats or mice (Bocan, et al, 1993). The 
normal level of cholesterol in rabbits is very low, and it is able to increase several fold 
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rapidly. The reason may due to the inability in increasing excretion of sterols (Kroon, 
et al, 1985, MacKinnon, et al., 1985, Thompson and Zilversmit, 1983). The high 
plasma cholesterol would promote the formation of foam cells and intima-media 
thickening. However, long term of high cholesterol diet causes high hepatotoxicity 
and extensive inflammation throughout the body (Prior, et al., 1961). Therefore, the 
1% cholesterol diet can only sustain for 12 weeks in the experiments. In some 
experiments, in order to produce advanced lesions that are similar to human, balloon 
injury would be done in the thoracic and abdominal aorta (Chea et aI., 2001, Hegyi, 
et aL, 2004，Ma, et al.，2008). However, considering the high risk and stress on the 
animals, the surgery was not applied in our study. 
Like in human, female rabbits would produce female sex hormone, making the 
accumulation of cholesterol much slower (Haarbo and Christiansen, 1996). Therefore, 
male rabbits were used to avoid the preventive effect of estrogen on atherosclerosis. 
Our rabbit model design was modified from another study (Zhang, et aL, 2005). 
However, the uniqueness of our study was the beginning time of DG extract treatment 
was after the formation of plaque, instead of the beginning of cholesterol diet. The 
time for the plaque formation was determined in the pilot study. 
4.1.3 Thiobarbituric Acid Reactive Substances 
The plasma samples from the rabbits contain thiobarbituric acid reactive 
substances, including lipid hydroperoxides and aldehydes, which are the side-products 
oflipid peroxidation. During lipid peroxidation, polyunsaturated fatty acids react with 
free radicals to form fatty acid radicals. The fatty acid radicals would react with 
oxygen molecules to form peroxyl-fatty acid radicals. The peroxyl-fatty acid radicals 
would in tum react with another fatty acid to form fatty acid radicals and a lipid 
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peroxide, and hence the above steps repeat again (Meagher and FitzGerald, 2000). 
In the assay, lipid hydroperoxides were decomposed in the presence of acid and 
metal to form Malondialdehyde (MDA), in which the concentration was determined. 
MDA reacted with thiobarbituric acid (TBA) to form an adduct, which could be 
detected spectrophotometrically at 532nm (Meagher and FitzGerald, 2000). The 
amount of TBARS was the indicator of the oxidative stress inside the plasma, which 
should be reduced if DG extract possessed anti-oxidative effect. 
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4.2 Methods 
4.2.1 Pilot Study for Establishment of Experimental Protocol 
The aims of the pilot study were to establish the effective dose of vitamin E as 
positive control, and the duration for the plaque to form after taking high cholesterol 
diet. These data would help us to design the experimental protocol for the actual 
animal study. Male New Zealand white rabbits of 3.0 to 4.0kg were used. After 1 
week of acclimatization and modification of diet (from the usual diet in Laboratory 
Animal Services Centers to the customized diet without supplement of cholesterol), 
rabbits were randomly divided into 5 groups. All groups were given at libitum assess 
to 1% cholesterol rabbit chow and water. Two groups of rabbits were daily fed with 
150mg/kg or 300mg/kg of vitamin E (serve as positive control) orally. The other three 
groups were given assess to 1% cholesterol diet for 4, 5, and 6 weeks (Li, et al., 1993)， 
respectively, without vitamin E treatments (Table 4.1). 
Table 4.1 Duration of treatment and sample size of each group in the pilot study 
Duration of Treatments Treatments Sample size 
4 weeks Water (2ml/kg) 2 
5 weeks Water (2ml/kg) 3 
6 weeks Water (2ml/kg) 2 
6 weeks 150mg/kg Vitamin E 2 
6 weeks 300mg/kg Vitamin E 2 
Tissue Sampling and Analysis ofEffect ofHigh Cholesterol Diet and Vitamin E 
After 4出，5出,and 6^ ^ week from the beginning of 1% cholesterol diet, one group 
of untreated rabbits were sacrificed by ketamin-xylazine anesthesia followed by heart 
puncture blood drainage. The vitamin E treated rabbits were sacrificed by the same 
method at the end of 6^ ^ week. The aorta was isolated from ascending aorta to the 
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celiac branch, clear of fat and excess adventitial tissue, rinsed with saline buffer and 
immersed into 1% Sudan III (w/v) in 70% alcohol (Zhang, et al., 2005) ovemight at 
room temperature. After staining, the aorta was washed using distilled water and cut 
in the mid-line to become a "Y" shape. The intima side of aorta was scanned with an 
Epson Perfection 1260 image scanner (Epson, Shinjyuku, Tokyo). 
Images were analyzed using Adobe Photoshop CS3 (Adobe, California, U.S.) by 
quantifying the total area and the Sudan III stained area (Red: 255, Green: 0, Blue: 0). 
Percentage of atheroma represented the extent of atherosclerosis. 
。， Sudan III Stained Area (Atheroma Area) 
o/o 01 Atheroma 
Total Area 
At 4th，5th, and 6^ ^ week, blood was collected before sacrifice. All rabbits were 
fasted for 12 hours before blood collection. Plasma was prepared from whole blood 
for total cholesterol, triglyceride and glucose measurements as stated in protocol 
2.4.2. 
Results and Implications on the Experimental Design 
Our results showed that the cholesterol diet induced atherosclerotic plaque 
formation throughout the duration of cholesterol diet. There was not much 
progression from week 4 to week 6 (Fig. 4.1 and 4.2). All dosages ofvitamin E tested 
could reduce the plaque formation. 300mg/kg of vitamin E exhibited slightly higher 
effect than 150mg/kg of it (Fig 4.2). Therefore, the treatment of DG extract began at 
the earliest time for plaque to emerge - 4出 week. The dose of vitamin E of 300mg/kg 
was found to be effectively inhibiting plaque formation and would be use as the 
positive control. 
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Fig 4.1 Representative photograph showing the effect of duration of cholesterol 
diet and vitamin E supplement on plaque formation. The patches stained in red by 
sudan III were the atherosclerotic plaque (indicated by arrows). Rabbits were fed with 
1% cholesterol diet only for with (a) 4 weeks; (b) 5 weeks; (c) 6 weeks; and rabbits 
fed with 1% cholesterol diet and (d) 150 mg/kg; (e) 300mg/kg of vitamin E 
supplement. 
14 ^ 
12 = ^ ~ 
^ ^ ^ f f l S 
4weeks 5weeks 6weeks 6weeks+ 6weeks + 
Vit E Vit E 
(150mgA:g/day) (300mg/kg/day) 
Weeks of 1% cholesterol treatment (+ Vit E supplement) 
Fig 4.2 The effect of duration of cholesterol diet and vitamin E supplement on 
aorta sections. Rabbits were fed with (a) 4 weeks; (b) 5 weeks; (c) 6 weeks of 1% 
cholesterol diet, and 1% cholesterol diet with (d) 150 mg/kg; (e) 300mgy^g ofvitamin 
E (n=2-3). Due to small sample size, no statistical analysis was conducted. 
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4.2.2 Effect of DG extract on Intima-media Thickening 
Male New Zealand white rabbits of 3.0 to 4.0kg were used. After 1 week of 
acclimatization and modification of diet (switched from the usual diet in Laboratory 
Animal Services Centers to the customized diet without supplement of cholesterol), 
rabbits were randomly divided into 6 groups. "Normal Diet" group and "Cholesterol 
Diet" groups were given at libitum assess to respective normal and 1% cholesterol 
rabbit chow and water. After 4^ ^ week, rabbits were fed daily with distilled water by 
oral gavage. The other 5 groups of rabbits were fed daily with distilled water, 
45.1mg/kg, 150mg/kg or 450mg/kg of DG extract dissolved in distilled water, or 
300mg/kg of vitamin E (as positive control) by oral gavage (Table 4.2). 
Table 4.2 Diet, treatment and sample size of each group 
Diet Treatments Sample size Sample size in 
inlstRun 2"^  Run 
Normal Diet Water (2ml/kg), as 3 1 
negative control 
1% Cholesterol Diet Water (2ml/kg), as 3 3 
negative control 
1% Cholesterol Diet 45.1mg/kg DG extract 4 2 
in water (2ml/kg) 
1 % Cholesterol Diet 150mg/kg DG extract 4 2 
in water (2ml/kg) 
1% Cholesterol Diet 450mg/kg DG extract 3 4 
in water (2ml/kg) 
1% Cholesterol Diet 300mg/kg Vitamin E, 3 3 
as positive control 
Blood Sample Collection and Analvsis 
Before the 1'^  week, and after the 4出 and 8出 week, the rabbit was restrained with 
a drape. 3ml ofblood was drawn from rabbit's marginal ear vein with the use of 10ml 
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syringe and 22G needle (Fig 4.3). Plasma was prepared as stated in protocol in section 
2.4.2. Total cholesterol, triglyceride and glucose assays were performed for first three 
samples. After 12^ ^ week, blood was collected by cardiac puncture blood drainage 
(Fig 4.3) under anesthesia. Total, HDL- and LDL-cholesterol, triglyceride, glucose 
and TBARS assay were done for the 12^ ^ week samples. All rabbits were fasted for 12 
hours before blood collection. 
g M | 
Random ^ g | H | H ^ H _ _ _ _ _ 
Grouping ^ ^ ^ ^ ^ K StartDG 
(n=6) :_"^ fHHPI^ R treatment 
I Start diet with or without • • Sacrifice the 
I 1% cholesterol 1 1 animal and 
• supplement ¥ * coUect aorta 
\ f 
I ~ y ^ ^ k^ 112 Weeks 
‘ t t t t 
Plasma Collection Plasma Collection Plasma Collection Plasma Collection 
^ ^ ^ ‘ ^ K V ^ ‘ ^ K ^ - by Cardiac Puncture 
8w Siw SBw ‘ j^' 
Fig 4.3 Timeline for the rabbit IMT study. 
Sampling of Animal Tissues 
After 12 weeks of treatment, the rabbits were sacrificed by ketamine-xylazine 
anesthesia followed by heart puncture blood drainage. The heart and liver tissue were 
collected and snap frozen in liquid nitrogen. The carotid arteries were isolated out and 
kept in 4% paraformaldehyde. The aorta was isolated from ascending aorta to the 
celiac branch, clear of fat and excess adventitial tissue, rinsed with saline buffer and 
divided into 5mm segments, which were then stored in 4% paraformaldehyde (w/v) in 
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PBS or snap frozen in liquid nitrogen. 
Quantification of Intima-media thickness 
The aorta sections that were 10mm proximal to heart were routinely dehydrated 
and parafFinized in an upright position. Serial sectioning was done, and 4 sections per 
aorta block were obtained. The sections were stained histochemically by routine 
haematoxylin and eosin (H&E) staining and mounted in permount. 
Images were digitized with a Nikon Eclipse TSlOO microscope G^ikon, Tokyo, 
Japan), equipped with Nikon Digital Sight camera and image analysis software NIS 
Elements F 3.0 (Magnification: 40X Exposure time: 200ms). 
The aorta image was merged using Photomerge function using Adobe Photoshop 
CS3 (Adobe, California, U.S.). The merged image was analyzed using Image J 0^IH). 
The margin of intima and media were drawn manually, according to the colour 
difference. The area of intima and media were quantified. The intima-media ratio was 
calculated and used as the parameter to assess the degree of atherosclerosis. 
I I n t i m a area | 
Intima-media ratio | 
Media area I 
4.2.3 Statistical analysis 
In blood profile assays, Mann-Whitney test was used to compare the data for 1% 
cholesterol diet group and normal diet group. Kruskal-Wallis test was used for 
comparison between the data for the 1% cholesterol diet groups with treatments and 
that of untreated 1% cholesterol diet group. 
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4.3 Result 
4.3.1 Study of the Anti-atherosclerosis Effect of DG extract - First Run 
Danshen-Gegen 7:3 water extract was tested for the therapeutic effect in intima 
media thickening in cholesterol-fed rabbit. In the first run (Fig 4.4 and Fig 4.5), 1% 
cholesterol diet induced a significantly higher intima-media (I/M) ratio. 300mgy'kg 
vitamin E significantly reduced the I/M ratio. Thus, both negative and positive 
controls were validated. There was a dose-dependent declining trend of I/M ratio after 
DG treatments and a significant difference was reached for treatment of 450 mg/kg 
DG extract. 
1% cholesterol diet had a trend of increasing plasma triglyceride (Fig 4.6 a), and 
reached a significant difference at 12^ ^ weeks, comparing with normal diet group. It 
also increased the plasma total cholesterol, reaching a significant different from 4^ 
weeks onwards (Fig 4.6 b). 1% cholesterol diet induced a significantly higher plasma 
LDL- and HDL-cholesterol at the end of the experiments (Fig 4.6 c,d, respectively). 
tVi tVi 
The plasma glucose level was significantly increased from 4 weeks to 8 weeks (Fig 
4.7). The amount of thiobarbituric acid reactive substances (TBARS), which reflects 
the lipid peroxidation, was in very low concentration (0.1 to 0.4 i^M) and did not 
show significant changes in all groups (Fig 4.8). 
The positive control, 300mg/kg vitamin E, caused a slight reduction in plasma 
triglyceride, and total cholesterol (Fig 4.6). However, significant difference was only 
reached at 8^ ^ week total cholesterol level (Fig 4.6 b). On the other side, 300 mg/kg of 
vitamin E slightly decreased the plasma glucose level, from 8^ ^ week (Fig 4.7). 
The formula under investigation, DG extract, showed an interesting trend. 45.1 
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mg/kg and 450 mg/kg of DG extract had a trend of reducing the plasma lipid level 
(Fig 4.6). Meanwhile, 150 mg/kg of DG extract did not modify the plasma lipid 
profile of the rabbits (Fig 4.6). All dosages of DG extract were not significantly 
affecting plasma glucose level (Fig 4.7). 
For the weight of the rabbits, all groups experienced a slight elevation in weight 
at the beginning. The weight continued increasing in normal diet group, remained 
stable in 45.1 mg/kg and 450 mg/kg of DG extract treatment groups and declined in 
150 mg/kg of DG extract treatments, vitamin E treatment and 1% cholesterol diet 
group (Fig 4.9). 
For the amount of diet intake, average daily intake (ADI) was recorded. Normal 
diet group had a higher ADI (range from 160-180g daily) than other groups. The ADI 
of the other groups were similar (range from 60-120g daily) with each other 
throughout the experiment (Fig 4.10). 
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Fig 4.4 Representative photographs showing effect of Danshen-Gegen 7:3 water 
extract on aorta intima thickness (1®^  Run). Smooth muscle cells are stained in deep 
pink and plaque were stained in light pink (indicated by arrows). All sections were 
10mm away from heart. The rabbits were fed with (a) normal diet; (b) 1% cholesterol 
diet; 1% cholesterol diet with DG extract of (c) 45.1mg/kg; (d) 150mg/kg, and (e) 
450mg/kg daily; and 1% cholesterol diet with (f) vitamin E of300mg/kg daily. 
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Fig 4.5 Effect of Danshen-Gegen 7:3 water extract on intima-media ratio (1®* 
Run). Sections were 10mm away from heart. All extracts/vitamin E/water were 
administered daily by oral gavage. 1% cholesterol diet group was compared with 
normal diet group. All data are presented in mean 土 SEM (n=3-4). 1% Cholesterol 
diet vs Normal diet using Mann-Whitney test, # p < 0.05; treatment groups vs 1% 
Cholesterol diet using Kruskal-Wallis test, * p < 0.05. 
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Fig 4.6 Effect of Danshen-Gegen 7:3 water extract on plasma lipid level in 
cholesterol-fed rabbits (1®^  Run). Plasma level of (a) triglyceride and (b) total 
cholesterol from 1'^  week to 12^ ^ week is shown. Plasma (c) LDL cholesterol and (d) 
HDL cholesterol for 12出 week is shown. All data are presented in mean 土 SEM 
(n=3-4). 1% Cholesterol diet vs Normal diet using Mann-Whitney test, # p < 0.05; 
treatment groups vs 1% Cholesterol diet using Kruskal-Wallis test, * p < 0.05. 
2S^ —‘—‘— — —-— — — 
i 
1 ^ # 也 T . , , 
‘ ^-^H mNornuilDiet 
I 150 i | | 丄 _ H^l^^l^ mi%Chol.Diet 
^ T_^ H ^ X ^ I H i i p H x , ODG(4S.lmg/kg) 
j 康 | f | L J H I • J • : 二 二 
• ^H • ^H • ^H • ^H mVit.E(300mg/kg) 
: i U U U I 
WKO WK4 WK8 WK12 
Fig 4.7 Effect of Danshen-Gegen 7:3 water extract on plasma glucose level in 
cholesterol-fed rabbits (1®^  Run). All data are presented in mean 士 SEM (n=3-4). 1% 
Cholesterol diet vs Normal diet using Mann-Whitney test, # p < 0.05; treatment 
groups vs 1% Cholesterol diet using Kruskal-Wallis test, • p < 0.05. 
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Fig 4.8 Effect of Danshen-Gegen 7:3 water extract on plasma TBARS level in 
cholesterol-fed rabbits (1'^  Run). All data do not show a significant difference. All 
data are presented in mean 土 SEM (n=3-4). 1% Cholesterol diet vs Normal diet using 
Mann-Whitney test, # p < 0.05; treatment groups vs 1% Cholesterol diet using 
Kruskal-Wallis test, * p < 0.05. 
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Fig 4.9 Effect of Danshen-Gegen 7:3 water extract on weight in cholesterol-fed 
rabbits (1'^  Run). All data were presented in mean +/- SEM (n=3-4). 
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Fig 4.10 Effect of Danshen-Gegen 7:3 water extract on food intake in 
cholesterol-fed rabbits (1®* Run). All data were presented in mean +/- SEM (n=3-4). 
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4.3.2 Study of the Anti-atherosclerosis Effect of DG extract - Second Run 
In order to confirm the result obtained from the first run, we started the second 
mn of the study. In the second run (Fig 4.12 and Fig 4.13), 1% cholesterol diet was 
however unable to induce a significantly higher intima-media (I/M) ratio. Thus, the 
cholesterol diet control cannot be established and the results of this run should be 
invalid. The intima-media ratio for cholesterol diet control is further investigated in 
Fig 4.11. Every section of aorta of rabbit 2 has plaque. However, I/M ratio in every 
section are not comparable to the results in 1'^  run. For rabbit 1 and 3, most of the 
sections did not have any plaque. In section 2 of rabbit 1 and 3, the I/M ratio was also 
unexpectedly low. These sections were Omm, lOmm, 20mm, etc. away from heart 
according to the ascending number. Nevertheless, we still analyze the data and 
investigate the possible explanation for that. 
A declining trend of I/M ratio with the increasing dose of DG extract was no 
longer observed. However, when comparing with the 1^ ^ run cholesterol diet control. 
150mg/kg and 450mg/kg ofDG extracts could still lower the I/M ratio. The positive 
control, vitamin E, was also having a low I/M ratio Fig 4.13. 
In Fig 4.14, cholesterol diet control was having a higher plasma triglyceride and 
cholesterol and 45.1mg/kg and 450mg/kg ofDG extract was able to reduce that, but 
no significant difference was seen. No elevation of plasma glucose was seen in 
cholesterol fed groups and no significant difference among groups were seen in 2"^  
run (Fig 4.15). The TBARS concentration remained very low in the 2"^  run (Fig. 4.16). 
The trends in the weight were similar in both runs (Fig 4.17)，with slight increase in 
weight at the beginning in all groups. About last 4 weeks, the weight remained stable 
for normal diet, 45.1mg/kg and 450mg/kg ofDG treatment groups, while declined for 
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cholesterol diet, 150mg/kg of DG treatment and 300mg/kg of vitamin E treatment 
groups. Lastly, the ADI in the 2"^  run is more stable than in the 1'^  run (Fig 4.18). 
Normal diet group had a higher ADI than other groups, while the ADI of the other 
groups were similar with each other throughout the experiment. These groups were 
having declined intake from week 5 to 9，a sudden increase in week 10 and dropped 
again after that. Overall, the blood profile and other trends (except I/M ratio) were 
similar to 1'^  run for all groups, although the trends were having less significance 
differences in 2"^  run. 
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Fig 4.11 The intima-media ratio of serial sections of aorta of rabbit fed with 1% 
cholesterol diet (2"^ Run). 
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Fig 4.12 Representative photographs showing effect ofDanshen-Gegen 7:3 water 
extract on aorta intima thickness (2"^ Run). Smooth muscle cells were stained in 
deep pink and plaque were stained in light pink (indicated by arrows). All sections 
were 10mm away from heart. The rabbits were fed with (a) normal diet; (b) 1% 
cholesterol diet, 1% cholesterol diet with DG extract of(c) 45.1mg/kg; (d) 150mgy^g; 
and (e) 450mg/kg daily; and 1% cholesterol diet with (f) vitamin E of300mg/1cg daily. - 1 1 1 - -
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Fig 4.13 Effect of Danshen-Gegen 7:3 water extract on intima-media ratio (2"^ 
Run). Sections were 10mm away from heart. All extracts/vitamin E/water were 
administered daily by oral gavage. All data are presented in mean 士 SEM (n=2-4) 
except normal diet group (n=l). Treatment groups vs 1% Cholesterol diet using 
Kmskal-Wallis test, * p < 0.05. 
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Fig 4.14 Effect of Danshen-Gegen 7:3 water extract on plasma lipid level in 
cholesterol-fed rabbits (2"^ Run). Plasma level of (a) triglyceride and (b) total 
cholesterol from 1'^  week to 12^ ^ week is shown. Plasma (c) LDL cholesterol and (d) 
HDL cholesterol for 12出 week is shown. All data are presented in mean 士 SEM 
(n=2-4) except normal diet group (n=l). Treatment groups vs 1% Cholesterol diet 
using Kruskal-Wallis test, * p < 0.05. 
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F b 4.15 Effect of Danshen-Gegen 7:3 water extract on plasma glucose level in 
cholesterol-fed rabbits (2"^  Run). All data are presented in mean 士 SEM (n=2-4) 
except normal diet group (n=l). Treatment groups vs 1% Cholesterol diet using 
Kruskal-Wallis test, * p < 0.05. 
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Fig 4.16 Effect of Danshen-Gegen 7:3 water extract on plasma TBARS level in 
cholesterol-fed rabbits (2"^  Run). All data do not show a significant difference. All 
data are presented in mean 士 SEM (n=2-4) except normal diet group (n=l). Treatment 
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Fig 4.17 Effect of Danshen-Gegen 7:3 water extract on weight in cholesterol-fed 
rabbits (2"^  Run). All data were presented in mean +/- SEM (n=2-4) except normal 
diet group (n=l). 
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Fig 4.18 Effect of Danshen-Gegen 7:3 water extract on food intake in 
cholesterol-fed rabbits (2"^  Run). All data were presented in mean +/- SEM (n=2-4) 
except normal diet group (n=l). 
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4.4 Discussion 
Atherosclerosis is a continuous pathological process involving stages of 
development and years to progress. To speed up the process and enable researcher to 
sample the tissue for further investigation, high fat diet-induced atherosclerosis in 
rabbit was developed. 
Results from the pilot study indicated that the plaque was formed before 4^ ^ week 
of 1% cholesterol diet. Therefore, treatment could start on the 4^ ^ week of high 
cholesterol diet. In other studies, vitamin E was commonly used in the control of the 
plaque formation (Hayashi, et al., 2005, Hegyi, et al, 2004, Okolie and Iroanya, 
2003). Our results provided experimental evidence to that. Vitamin E functions as an 
antioxidant, which can scavenge the reactive oxygen species (ROS) (Chiu and Taylor, 
2007，Halliwell, et al, 1992). The reduced amount ofROS causes a reduced oxidation 
of LDL cholesterol. As the level of oxLDL decline, the progression of atherosclerosis 
would also slow down. Moreover, vitamin E can help attenuating the progression of 
atherosclerosis through inhibition of vascular SMCs proliferation (Boscoboinik. et al., 
1991)，inhibition of platelet aggregation (Murohara, et al., 2002), and the reduction of 
the expression of soluble cell adhesion molecules (van Dam, et al, 2003). It can also 
reduce the risk of atherosclerosis by inhibition of leukotrienes production and 
promotion of prostacyclin production (Tran and Chan, 1990). Most importantly, the 
dose used in our study did not exert toxic effect on the rabbits. The results supported 
the use ofvitamin E as the positive control. 
In our experiments, the main finding was the significant and dose dependent 
reduction in the intima-media ratio by treatment of different concentrations of DG 
extract. The sections were positioned at the aortic arch. The sections in V^  run were 
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verified to locate at the aortic arch by their curvature. In Fig 4.19, the curvature ofthe 
section is shown. This should due to the fact that atherosclerotic lesion initiates at 
branching points of arteries and regions with disturbed blood flow (Cunningham and 
Gotlieb, 2005). DG extract-treated rabbits exhibited dose dependent reduction in 
intima-media thickness. The effect of 450mg/kg DG extract was comparable with that 
of 300mg/kg vitamin E. In addition, the plasma total, HDL- and LDL- cholesterol 
levels were lowered in 45.1 or 450 mg/ml DG extract-treated rabbits comparing with 
those on cholesterol diet only. 
— r^Mjj| i ^ ^ H ^ H H ^ ^ H ^ H | ^ H ^ ^ B ^ ^ H 
^ j i ^ ^ m m ^ i 
fll^H 
^^ ^^ H ^ ^^ ^^ ^ 
::•�~^,:^!!ffiSmRS99B9HHHIHm^|||||^^| ^B^^^^ |^^ ^^^ |^^ mi^ ^^mH^^^^^^^^^ |^ 
Fig 4.19 Representative photo for aortic arch and descending aorta (Left) the 
section 10mm away from heart, which is curve in nature; (Right) the section 70mm 
away from heart, which is straight in nature. 
45.1 or 450 mg/ml DG extract-treatment could maintain the weight ofthe rabbits 
during the last few weeks, while vitamin E treatment or cholesterol diet without 
treatment would cause reduction in weight in the last few weeks. Since the amounts of 
diet intake were similar, the weight reduction should due to deterioration of general 
health condition of the rabbits. During the experiment, two groups of rabbits, one 
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from cholesterol diet group and one from vitamin E treatment group, lost over 25% of 
their initial weight. The wasting was too serious, below the ethical standard and were 
euthanatized. The health maintenance effect of DG extract was possibly due to the 
reduced intima-media thickness, as atherosclerosis is secondary to many body 
disorders or conditions like hypertension, diabetes, propensity to form thrombi and 
level of homocystine. However, the situation may also be vice versa. Reduced 
atherosclerosis can be the cause of a better health condition. Other study revealed that 
better, less resistant blood flow is critical to the health condition (Morris and 
Blumgart, 1957). But no matter which is the truth, the quality of life of the DG 
extract-treated rabbits was improved. This improvement was even not observed in 
vitamin E-treated group. 
TBARS include lipid hydroperoxides and aldehydes, which increase as a result 
of oxidative stress. Our results showed that there was no significant differences in 
TBARS among all tested groups. The concentration ofTBARS was only 0.2 to l.O^M, 
which is very low in the assay. Therefore, the results might not have been correctly 
reflected the real situation, as bioactive compound in Danshen 0^iu, et aL, 2000, 
Wang, et al, 2003, Zhao, et al., 1996) and Gegen (Finking, et al.’ 1999, Huang and 
Shi, 1996，Rimbach, et al, 2008) were commonly reported for their anti-oxidative 
function. The comparisons are summarized in Table 4.3. 
In the second run of the rabbit study, 1% cholesterol diet without drug treatment 
was unable to induce intima-media thickening, while 1% cholesterol diet with drug 
treatment are having intima-media thickening, is completely opposite to the results 
observed in the first run. The blood profiles ofthese rabbits however match the first 
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cholesterol diet was working normally. The trend of ADI and body weights were also 
matched with those of the first run of rabbits. Therefore, the difference should not due 
to the difference in intake of cholesterol diet. The slides were also checked to be 
match in shape with the paraffinized samples. So, the slides were named correctly. In 
order to check the possibility of displaced plaque, all eight sections of the affected 
rabbits were stained and have I/M ratio calculated. No large extent of intima-media 
thickening was seen in any section. From other studies, the sections were also taken 
from the aortic arch but not the other locations (Alfon, et al., 1999，Boger, et al.，1998, 
Choe, et al, 2001, Maranhao, et al., 2008). Thus, the reason of the absence of 
intima-media thickening is unknown. 
Conclusion 
In conclusion, DG extract could protect the New Zealand white rabbits from the 
progression of atherosclerosis in a dose-dependent manner. Hypocholesterolemic 
effect of DG extract on these hypercholesterolemic rabbits was also shown. DG 
extract was also found to improve the health condition in terms of reduced weight 
drop. However, anti-oxidative effect of DG extract was not found in this study. Due to 
the inability of cholesterol diet to induce intima-media thickening in the control group 
of the second run of the rabbit study, verification of the results can be included in the 
further studies. The same study should be repeated in the near future in order to 
confirm the results. 
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Chapter 5 
General Discussion and Conclusion 
5.1 Significance of the Study 
Cardiovascular diseases (CVD) are one of the most prevalent diseases in the 
world. It is also one of the top mortality causes. Treatment and management of CVD 
pose a heavy burden to the economy. Hence, prevention or suppression of the diseases 
in an economical way becomes a target of research. Although progression of CVD is a 
complex and inter-related process, hypertension and atherosclerosis are the common 
risk factors for CVD. Hypertension is also a main risk factor for atherosclerosis. 
Therefore, the study starts from the investigation of the anti-hypertensive effect of DG 
extract, and proceed to the research of anti-atherosclerotic effect of DG extract. 
In international research field, compound formula seldom becomes the target for 
research, due to its complexity and multiple compound nature. However, most of the 
Chinese medicine formulations include multiple herbs, and these herbal formulae 
were used in China for thousands of years for treatment of diseases. Danshen and 
Gegen were commonly used in the treatment of cardiovascular diseases. Therefore, 
investigation of DG compound formula become our research target and is exclusively 
investigated by our research team. In the previous studies (Leung, 2003), different 
ratio combination of DG {Pueraria thomsonii as Gegen) was tested using red blood 
cell hemolysis assay, which mainly test for the anti-oxidation power of DG extract. 
The ratio of DG in 7:3 was determined to be the best combination and used in the 
later studies, which DG 7:3 performed better than the same dose ofDanshen or Gegen. 
After a series of in vitro, ex vivo and in vivo biological assays, DG {Pueraha 
thomsonii as Gegen) compound formula was found to be effective in antioxidant 
(Chan, 2006，Koon, 2006), cardioprotection, vasodilation (Chan, 2006), 
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anti-hypertension and anti-atherosclerosis (Koon, 2006, Tam, 2004). 
Previously, anti-hypertension experiments were carried out to test for the effect 
of DG extract on systolic blood pressure. However, the related species Pueraria 
thomsonii was used as Gegen in some of the previous studies. The ongoing studies are 
using the other species Pueraria lobata as the standardized Gegen, as mention in the 
most recent Chinese Pharmacopoeia (Chinese Pharmacopoeia Commission, 2010). 
The present study also tested for the efficacy of the dose of DG formula (Human 
equivalent dose (HED) = 45.1mg/kg in rats) that is used in the current clinical trial. It 
was found that the new dose, which is only one-third of the previous dose (HED = 
150mg/kg in rats), can still achieve the same efficacy as the previous dose in both 
preventive and therapeutic experiments. These findings consolidate the 
anti-hypertensive effect of DG extract and reconfirm the use of Pueraria lobata as 
Gegen would not adversely affect the effectiveness of DG extract. The positive effect 
of the new dose of DG extract gives a solid evidence to support the current clinical 
trial. 
The vasodilative actions of DG extract on aorta rings isolated from the DG 
extract-fed SHR rats were tested. Their ACh-induced relaxation profiles were similar 
to those of SHR rats of control group under the situation without inhibitors added, or 
with NO-pathway inhibitor, or prostacyclin-pathway inhibitor, or with 
hyperpolarization-pathway blocker added. Our results are consistent with the results 
of previous studies where no inhibitors added, or with NO-pathway inhibitor added. 
However, the results also showed that the maximum relaxation percentage of SHR 
rats is lower than those of the normotensive WKY rats, and that DG extract treatments 
have a trend to increase the relaxation. In addition, the DG extract treatments 
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alleviated the contractile force during Phe induction. 
Comparing with the previous vasodilation studies (Chan, 2006), the main 
difference of the present study is the inclusion of different concentrations (0.25 to 
2mg/ml) of DG extract, whereas a single concentration was used previously, and also 
tested for the involvement of BKca and KAip channels. The significance of different 
concentrations of DG extract is to ensure the results are not underestimated by 
insufficient dose used. Besides, the vasodilative effect of DG extract is thought to 
involve multi-mechanisms. Our study prevents the overdose of DG extract shading 
the inhibitory effect of the inhibitor or blocker added, which may cause a false 
negative result for an involved mechanism. The new pathways investigation is based 
on the findings that BKca and KAip channels were found to be related to actions of the 
bioactive components of Danshen and Gegen (Chan, et al., 2009，Sun, et al., 2007). 
To be consistent with the other experiments in this study, same batch of DG extract 
was used in the entire study. 
The results of present studies showed that the DG extract-induced relaxation is 
endothelium-independent, neither NO-mediated nor prostacyclin-mediated. In fact, 
the relaxation depended on the hyperpolarization. Both Kir channels and Ky channels 
were involved in the vasodilation in these concentrations. These findings were 
consistent with the previous studies (Chan, 2006) (see Table 3.5), which focused on a 
single concentration of DG {Pueraria lobata as Gegen) formula. Our study also 
demonstrated that the relaxation involves ofKAip channels and was unrelated to BKca 
channels. Our study also suggested that the vasodilative action has multi-targets. As 
the vasodilative action was endothelium-independent, explanations involving 
endothelium were excluded. Some other possible mechanisms, such as inhibition of 
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calcium influx through calcium channels, inhibition of myosin light chain kinase, or 
activation of myosin light chain phosphatase, are still warrant further investigations. 
Detailed elucidation of these mechanisms will be the target of further research. 
Apart from the current study, we have previously tested the effect of DG extract 
on diet-induced atherosclerosis in rabbits (Koon, 2006). The comparisons are 
summarized in Table 4.3. However, in the previous study, DG extract was mixed to 
the diet, which was susceptible to denaturation. Besides, the amount of DG extract 
intake depended on the diet intake of rabbits, which was shown to be decreasing in the 
later stage of the study. Thus, the DG extract doses were not accurately controlled. 
Furthermore, only quantity of the atherosclerotic plaque was determined. But in the 
real situation, stenosis and blockage of blood flow were the main cause to the 
complications. Hence, improvements were made in the current study by using a daily 
oral gavage of freshly prepared DG extract in aqueous solution form. This method 
mimics the intake practice of human and gives a precise intake of DG extract to 
rabbits, ensuring an accurate dose of treatment. In addition, instead of quantity of 
plaque, the thickness of the plaque, namely intima-media thickness, was investigated 
with histochemical methods. 
Our results showed that DG extract could reduce intima-media thickening in a 
dose dependent manner. The effect of 450mg/kg DG extract was comparable to that of 
300mg/kg vitamin E, which is a positive control. Combining with our previous results, 
we concluded that DG extract reduces the atherosclerotic plaque in both quantity and 
thickness, which could be partially explained by the slight hypocholesterolemic effect 
of DG extract. Moreover, base on our previous in vitro studies of our institute, DG 
extract also reduced endothelial-monocyte adhesion (Koon, 2006), which is critical 
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for the initiation of atherosclerosis. The protein responsible for the penetration of 
monocytes through the endothelium and remain in intima, MCP-1, was also found to 
have reduced production with the addition ofDG extract previously (Koon, 2006). As 
for the later stage of atherosclerosis, SMC proliferation and migration plays an 
important role in thickened, fibrous intima. Inhibitory effect of DG extract on vascular 
SMC was previously verified by ^H-thymidine uptake assay and cell cycle analysis 
(Koon, 2006). The migration of vascular SMC was also inhibited by DG extract in 
transwell assay (Koon, 2006). All these parameters would be responsible for the 
anti-atherosclerosis efFects of DG extract. Therefore, further studies can be performed 
on the action mechanisms of DG extract on anti-atherosclerosis, which is expected to 
be a complex process involving cytokines, adhesion molecules and different proteins. 
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5.2 Limitations and Future work 
For the therapeutic effect study on SHR rats in hypertensive state, the main 
limitation of our study is the extremely high systolic blood pressure of about 
200mmHg, which is not close to the reality in human. Another limitation is the small 
difference between the relaxation of WKY and SHR rats' aorta. As mentioned before, 
older rats perform better in this assay since older SHR rats were known to have 
increased stiffness in blood vessels (Safar and Laurent, 2003). This could result in a 
larger difference in stiffness in aorta between WKY and SHR rats. The stiffness in 
aorta would affect its performance on vasodilation in the organ bath. Therefore, 
further study should be performed using older rats of above 24 weeks old at the time 
of sacrifice. Their aorta could be sampled for the vascular reactivity test. 
Another limitation is the doses of DG extract used in organ bath for mechanism 
elucidation have a weak linkage with the clinical dose. The DG extract was directly 
added to the aorta ring. Therefore, the dose should be linked to the plasma dose in DG 
extract in vivo. To investigate that, the bioavailability should be considered. The 
plasma concentration of markers of DG extract, like salvianolic acid B，Tanshinone II 
A, puerarin and daidzin, can be determined by HPLC after oral gavage of a known 
dose of DG extract. With the information on the bioavailability, the linkage between 
the dose ofDG extract used in organ bath and the clinical dose can be estimated. 
There are various follow up studies that can be done in the future. In 
investigation of mechanism of DG extract-induced vasodilation, unidentified 
pathways are the main target in the future. Other studies showed the possibility of 
involvement of myosin light chain kinase (MLCK) or myosin light chain phosphatase 
(MLCP) in the action of another herbal extract (Park, et al., 2009). Inhibitors for 
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MLCK and MLCP, which are ML-9 and Calyculin A, respectively, can be included to 
test if DG extract affects their expression or actions. The other possibility includes the 
blocking effect on calcium channels. After depolarization, influx of calcium ions 
through voltage dependent calcium channels causes increase of intracellular calcium 
level. Intracellular calcium binds with myosin light chain and mediates 
vasoconstriction. The blockage of calcium channels by DG extract, if happens, can 
reduce the intracellular calcium and inhibit vasoconstriction. The inhibitory effect can 
be verified by testing CaCl2-induced vasoconstriction (Lam, et al, 2006) in different 
concentrations of DG extract. 
With the setup of blood pressure measurement on SHR rats for studying 
anti-hypertensive effect, ex vivo vascular reactivity assay for mechanism elucidation 
and in vivo confirmation of the mechanism, we have now established a platform with 
in vivo and ex vivo assay for investigation of anti-hypertensive effect and mechanism 
of potential herbs or drugs. This platform can be used to assess the vasodilation 
mechanism of Danshen, Gegen and their individual active components. This can 
certainly help in the mechanism elucidation of this formula and reveal the potential 
involvement ofthe bioactive components in this formula in vasodilation. In the future 
research of other vasodilative herbs, the same platform can also be used. The 
standardized platform enables us to assess and compare the vasodilation efficacy of 
different formula, herbs or single compound easily. This comparison can help us to 
fiiid a better formula and any potential herbs for anti-hypertension, which should be 
the final goal of the research. 
In order to verify the effect of positive control raloxifene experiment, a better 
setup ofthe study is to include a group of WKY rats treated with raloxifene. This can 
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ensure raloxifene has no adverse effects on rats. Moreover, a better choice of positive 
control is to use the commonly prescribed western medication for anti-hypertension, 
like the ACE inhibitors. Another improvement is to include the assays of the plasma 
salts, such as potassium, sodium and calcium levels. As depletion or retention of salt 
is often seen in anti-hypertensive drugs, e.g. diuretics and calcium channel blockers, 
the tests of contents of these salts determine whether DG extract exhibits any effect in 
salts content. 
Besides, hypertension may also be related to the heart. A more rapid heart rate or 
a larger contractile force of the heart can also lead to larger blood flow, resulting in 
hypertension. Therefore, the effect of DG extract on heart rate and beating pattem can 
be monitored by electrocardiogram in vivo, while the contractile force and relaxation 
can be monitored by Langendorff isolated heart perfusion system ex vivo in rats. 
For the anti-atherosclerosis study, the main limitation is rabbits' inability to form 
advanced lesions without balloon surgery. Therefore, if treatment of advanced lesions 
is the future research target, the study should be repeated with balloon surgery 
performed on thoracic or abdominal aorta. Moreover, although DG extract showed a 
dose-dependent anti-atherosclerosis effect in the first run of rabbit study, the high 
cholesterol-diet control in the second run showed unexpected low intima-media 
thickness. There was also no displacement of plaque in rabbits in the second run. Due 
to time-limitation, another run of the rabbit study is not available. However, the same 
study will be repeated in the future to confirm the observation. Nevertheless, as an 
improvement of the study, infiltration of macrophages, migration and proliferation of 
smooth muscle cells (Djahansouzi, et al.，2001, Hegyi, et uL, 2004, Rosenfeld and 
Ross, 1990), expression of adhesion molecules (ICAM-1 and VCAM-1) (Broisat, et 
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al., 2007, Choe, et aL, 2001, Iiyama, et al., 1999) can also be considered. 
Thiobarbituric acid reactive substances (TBARS) assay is an index of lipid 
peroxidation (Buege and Aust, 1978). The previous test on TBARS did not provide 
adequate information for the anti-oxidative effect induced by DG extract even if it has 
that effect. As a follow-up study, the anti-oxidative effect can be tested on 
copper-mediated oxidation of isolated LDL (Burstein. et aL 1970) or serum in the 
future. Formations of conjugated diene and lipid hydroperoxides (Barnes, et al.，2002, 
Visavadiya, et al., 2009), which are the better indicators for lipid oxidation can also 
be examined. By doing these, it should give a full picture on the anti-oxidative effect 
of DG extract on preventing lipid oxidation in vitro and in vivo. If the results are still 
negative, then anti-oxidation is unlikely to be the mechanism responsible for reduced 
IMT caused by intake of DG extract. 
For the anti-atherosclerotic study, we have so far covered the therapeutic effect 
of DG extract. Future study can also look at the preventive effect of DG extract on 
intima-media thickening, i.e. by giving DG extract and 1% cholesterol diet together at 
the beginning of the study before the plaque was formed. The combined results would 
enable us to have a complete picture on whether DG extract possessed the 
anti-atherosclerotic effect in both preventive and therapeutic aspects. 
Alternative animal models can also be considered. The main limitations of 
current SHR rat include 1) too high pressure; and 2) fixed period and long duration 
for generation of hypertension. For angiotensin-induced hypertensive model, the rats 
have the advantage of having relatively lower blood pressure of about 170mmHg 
(Kane, et al., 2010, Walter, et al., 2008), which is closer to the reality as in human. 
Dahl salt-sensitive hypertensive rat is another choice. The rat can be used if a more 
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rapid increase in blood pressure, or the research is target specifically on salt-sensitive 
hypertension (Garrett, et aL 2000). Both models can have hypertension induce at the 
desired time. However, these rats need extra intake of other drugs or salt for induction 
of hypertension and the successful induction may also be affected by individual 
response. For atherosclerotic model, ApoE-deficient mice are also commonly used as 
an alternative of rabbits (Meir and Leitersdorf, 2004). The use of mice enables a 
larger sample size, as rabbits are space occupying. Intragastric intake ofwater extracts 
for rabbits is also time-consuming and has a higher risk of aspiration pneumonia. 
However, rabbit model for studying IMT was established for much longer time. 
Rabbits also have the advantage of having larger quantity.of tissue available for 
sampling than mice. Therefore, other animal models may be considered for further 
studies. 
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5.3 Clinical Implication ofthe Use ofthe DG Preparations for Patients with CVD 
The previous clinical study found that DG extract could have beneficial effect on 
atherosclerosis-related parameters in patients with coronary artery disease, such as 
reduction in total and LDL-cholesterol, improvements in vasodilation (flow-mediated 
or nitroglycerin-induced) and reduction in IMT (Tam, 2004). In our studies, DG 
extract exhibited anti-hypertensive effect in the in vivo rat model and ex vivo organ 
bath models, and possibly anti-atherosclerotic effect in in vivo rabbit model, through 
vasodilative and hypocholesterolemic action. 
We would recommend the use of DG extract as alternative medication in patients 
diagnosed as higher normal to mild hypertension (Table 1.1) based on the clinical and 
non-clinical experimental results. The extract is also recommended for patients with 
atherosclerosis as DG extract can reduce the intima-media thickness in clinical trial 
and possibly in animal study. In addition, the hypocholesterolemic effect of DG 
extract observed in clinical study and the trend in our animal study also suggest the 
recommendation of its use in the control of hypercholesterolemia. 
Although the anti-hypertensive and anti-atherosclerotic effects of DG extract is 
promising, the interactions of DG extract with other commonly used conventional 
cardiovascular medications like statin, warfarin or other vasodilators are unknown. If 
synergistic effect exists, the adverse events can be serious. Hence, the use of DG 
preparation together with other drugs should be with caution. The interactions of DG 
extract with these drugs should be investigated in details in the future studies. 
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5.4 Conclusion 
The present study shows that DG extract induces a dose-dependent, 
endothelium-independent vasodilation on isolated aorta of SD rats. Potassium 
channels, especially Kir, Ky and KAip channels, are likely to be involved in the aortic 
vasodilation, while the involvement of extra mechanisms are also expected. This 
pharmacological effect, combining with a lower contractile force, can explain the 
anti-hypertensive effect of DG extract in SHR rats in this study. In another part of 
present study, DG extract is able to slow down IMT progression. 
Hypocholesterolemic effect of DG extract is likely to be involved in the 
anti-atherosclerosis process. As DG extract can have positive effects on hypertension 
and atherosclerosis, which are the main risk factors for CVD, our study provide 
scientific evidence to support the previous and current clinical trial on DG extract's 
anti-atherosclerosis effect. 
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